Articles of Journal of Japanese Society of Pharmaceutical Oncology | Volume 25, Issue / 2022

Search by Journal

HOME
> Search by Journal
> Journal of Japanese Society of Pharmaceutical Oncology

Journal of Japanese Society of Pharmaceutical Oncology

Volume 25, Issue / 2022

English Article

Japanese Article

Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.

	P-001. Time analysis of the thrombocytopenia expression with the Azacitidine administration 安田昌宏, 舘知也, 大澤友裕, 渡邉久高, 井上誠二, 牧野哲平, 長屋雄大, 森田美穂, 田中和秀, 田中佑佳, 青山智, 笠原千嗣, 寺町ひとみ, 水井貴詞 Journal of Japanese Society of Pharmaceutical Oncology 25: 1-1, 2022.

	P-002. Change of infusion reaction frequencies at the rituximab administration by the difference of preventive preparation 内藤義徳 Journal of Japanese Society of Pharmaceutical Oncology 25: 2-2, 2022.

	P-003. Examination of the DEX consumption in the moderate emetic risk regimen in consideration of a pneumocystis pneumonia onset risk 増野貴司, 櫻井望, 中山和彦, 桜沢千世, 小幡輝夫, 茂木充 Journal of Japanese Society of Pharmaceutical Oncology 25: 3-3, 2022.

	P-004. Study of the factor having an influence to pharmacokinetics at the tapentadol oral administration in patients with cancer pain 本間雅士, 国分秀也, 平山武司, 奥脇興介, 堅田親利, 林経人, 金井昭文, 厚田幸一郎 Journal of Japanese Society of Pharmaceutical Oncology 25: 4-4, 2022.

	P-005. The handling situation of regorafenib and trifluridine/Tipiracil in the unresectable progress recurrence colon cancer late line treatment in the health insurance pharmacy 照屋千津子, 野々原育子, 土橋美和 Journal of Japanese Society of Pharmaceutical Oncology 25: 5-5, 2022.

	P-006. Fact-finding study on aprepitant combination in the high-dose Carboplatin-containing regimen 白神霞, 池田賢二 Journal of Japanese Society of Pharmaceutical Oncology 25: 6-6, 2022.

	P-007. A treatment evaluation and side effect of PRO-CTCAE evaluation using the G8 in patients with elderly people blood-forming organ tumor 平川正宏, 東謙司朗, 得能成美, 高濱啓太, 鈴島仁, 下村泰三, 森岡淳子 Journal of Japanese Society of Pharmaceutical Oncology 25: 7-7, 2022.

	P-008. Effect on renal function in the short hydration method 古舘晶弘, 平井成和, 土井啓員, 佐野君芳, 増田雅行 Journal of Japanese Society of Pharmaceutical Oncology 25: 8-8, 2022.

	P-009. About the intervention effect of the pharmacist in foreign cancer chemotherapy-treated patients 宮内康夫, 櫻井淳二, 八島一史, 岡田優, 佐々木美織, 加藤さゆり, 佐藤伸輔, 松尾幾 Journal of Japanese Society of Pharmaceutical Oncology 25: 9-9, 2022.

	P-010. Fact-finding of the adverse event of the Atezolizumab nab-paclitaxel therapy in the PD-L1-positive inoperability or recurrent triple negative breast cancer 江原美里, 宮城和代, 畑裕基, 山下大輔, 井上敦介, 吉野宗宏 Journal of Japanese Society of Pharmaceutical Oncology 25: 10-10, 2022.

	P-011. An interview sheet for immune-mediated adverse event early detection using PRO-CTCAE and operation in the pharmacist outpatient department 堀切美里, 合津貴志, 関根悠, 田崎政則 Journal of Japanese Society of Pharmaceutical Oncology 25: 11-11, 2022.

	P-012. Questionnaire results and infusion time error, the 5-FU rest rate analysis results that patients received about the pump before and after the infusor pump change after the infusion 尾崎智規, 堀智貴, 武知理菜子, 中川智章, 森田淳子, 御堂恵里佳, 牧浦耕平, 吉岡奈津恵, 北村芽衣子, 生島繁樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 12-12, 2022.

P-012. Questionnaire results and infusion time error, the 5-FU rest rate analysis results that patients received about the pump before and after the infusor pump change after the infusion
尾崎智規, 堀智貴, 武知理菜子, 中川智章, 森田淳子, 御堂恵里佳, 牧浦耕平, 吉岡奈津恵, 北村芽衣子, 生島繁樹
Journal of Japanese Society of Pharmaceutical Oncology 25: 12-12, 2022.

	P-013. Examination of the relationship with the expression situation and anemia of the taste disturbance in our hospital in the colon cancer CapeOX therapy 高木麻衣, 伊藤文香, 中村智絵, 宮崎雅之, 山田清文 Journal of Japanese Society of Pharmaceutical Oncology 25: 13-13, 2022.

	P-014. Look at the multicenter rear about the onset of denosumab-induced hypocalcemia in patients with renal failure solid carcinoma; a mark observational study 山本圭祐, 澤昇平, 中村和代, 嘉屋道裕, 柳澤由紀, 高屋敷奈々, 浮田浩利, 名倉真理子, 杉上香織, 北島真利子, 平野公美, 石田紘基, 小野田千晴, 小林豊, 中谷英仁, 名波章子, 小田切圭一, 矢部勝茂 Journal of Japanese Society of Pharmaceutical Oncology 25: 14-14, 2022.

P-014. Look at the multicenter rear about the onset of denosumab-induced hypocalcemia in patients with renal failure solid carcinoma; a mark observational study
山本圭祐, 澤昇平, 中村和代, 嘉屋道裕, 柳澤由紀, 高屋敷奈々, 浮田浩利, 名倉真理子, 杉上香織, 北島真利子, 平野公美, 石田紘基, 小野田千晴, 小林豊, 中谷英仁, 名波章子, 小田切圭一, 矢部勝茂
Journal of Japanese Society of Pharmaceutical Oncology 25: 14-14, 2022.

	P-015. The use of olanzapine situation of the antiemesis purpose in patients with foreign cancer chemotherapy enforcement 高木淳也, 海野祥生, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 25: 15-15, 2022.

	P-016. The adverse event expression of our hospital situation investigation in the Pola+BR therapy regimen 三浦裕馬, 奥村俊一, 殿村直也, 清美奈, 石原溶子, 八木悠, 下山達 Journal of Japanese Society of Pharmaceutical Oncology 25: 16-16, 2022.

	P-017. Review of the antiemetic at the XELOX therapy 大畑茂樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 17-17, 2022.

	P-018. The clinical effect that pazopanib and the drug interactions with the gastric-acid secretion antagonist result in 平井成和, 有山智博, 池本美南都, 土井啓員, 増田雅行, 石井敏浩 Journal of Japanese Society of Pharmaceutical Oncology 25: 18-18, 2022.

	P-019. The effect that side effect expression in the before cancer of the esophagus, introduction DCF therapy gives to anticancer agent doses 東山倫子, 毛利順一, 新角郁歩, 菅原充広, 堅田親利, 平山武司, 厚田幸一郎 Journal of Japanese Society of Pharmaceutical Oncology 25: 19-19, 2022.

	P-020. Effect on evaluation and clinical practice of the antiemesis effect of palonosetron and granisetron in the platinum-containing chemotherapy 横田敦子, 吉澤朝枝, 山崎朋子, 荒川雄一朗, 田島英, 塩月智子, 櫻澤有紀 Journal of Japanese Society of Pharmaceutical Oncology 25: 20-20, 2022.

	P-021. Progress, the effect that proton pump inhibitor combination gives for a low Mg blood symptom by the panitumumab in the patients with recurrent colon cancer impossible of curative resection 坂本美咲, 八木聡美, 中村智絵, 溝口博之, 山田清文 Journal of Japanese Society of Pharmaceutical Oncology 25: 21-21, 2022.

	P-022. Investigation about the eruption frequencies in Fukuyama Municipal Hospital urology department GEM treated patients and an expression-related factor and the readministration 池田敦, 小林恭輔, 荻野裕介, 岩永崇志, 寺岡美智子, 森光保武, 藤井秀一 Journal of Japanese Society of Pharmaceutical Oncology 25: 22-22, 2022.

	P-023. About the effect of the expression situation of retching, vomiting of the TAS-102, TAS-102+Bev therapy in our hospital and the supportive care drug which we used 馬場亮一, 岡田昌之, 成末まさみ Journal of Japanese Society of Pharmaceutical Oncology 25: 23-23, 2022.

	P-024. Fact-finding of irAE and the examination monitoring with the immune checkpoint inhibitor in our hospital 傅恵美, 榎本英明, 赤地真実, 木城美保, 石丸博雅, 後藤一美 Journal of Japanese Society of Pharmaceutical Oncology 25: 24-24, 2022.

	P-025. Investigation about the effectiveness, the safety under the use of the sustained G-CSF preparation in the FOLFOX regimen for progress recurrence colon cancer 櫻田直也, 大登剛, 土屋裕伴, 新井亘, 増田裕一 Journal of Japanese Society of Pharmaceutical Oncology 25: 25-25, 2022.

	P-026. It is examined blood poison characteristics with the peg filgrastim (PEG-G) administration for the chemotherapy regimen for every two weeks 坂本有里恵, 井上智恵, 日生下美紀, 西窪奈津子 Journal of Japanese Society of Pharmaceutical Oncology 25: 26-26, 2022.

	P-027. About an outcome by the evaluation of low Dors/long interval of the prostate cancer docetaxel therapy and the intensity of treatment reinforcement after PD 岡田昌之, 馬場亮一, 成末まさみ Journal of Japanese Society of Pharmaceutical Oncology 25: 27-27, 2022.

	P-028. Fact-finding of Steroid-sparing in our hospital at checkpoint inhibitor and chemotherapy combination of immunity 新村航, 山口佳津騎, 越野優希, 鈴木聖, 田中裕章, 小坂信二 Journal of Japanese Society of Pharmaceutical Oncology 25: 28-28, 2022.

	P-029. Risk factor investigation of comparison between granisetron and antiemesis effect of palonosetron in the gynecologic cancer TC therapy and retching, vomiting 佐々木真理, 酒向あずみ, 関口昌利 Journal of Japanese Society of Pharmaceutical Oncology 25: 29-29, 2022.

	P-030. A fact and examination of hepatic dysfunction with the immune checkpoint inhibitor 新田健太郎, 野田沙織, 橋爪顕子, 加納嘉人, 石川敏昭, 三宅智 Journal of Japanese Society of Pharmaceutical Oncology 25: 30-30, 2022.

	P-031. Investigation of the inquiry situation to a hospital at adverse event expression in patients who received Atezolizumab/bevacizumab combination therapy 若林茜, 粂哲雄, 金子美智子, 鴨志田武, 櫻井美満, 片山宏章, 藤井秀一, 田中大智, 石川寛, 篠道弘 Journal of Japanese Society of Pharmaceutical Oncology 25: 31-31, 2022.

	P-032. Study on factor giving it to transient elevated blood pressure during the Bevacizumab administration in patients with colon cancer 小池慶彦, 佐藤陸, 加藤裕芳, 日浦寿美子, 小林秀樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 32-32, 2022.

	P-033. The effect that dexamethasone administration after day2 gives to retching, vomiting of the late start period on modified FOLFIRINOX therapy 後藤真実, 増島広幸, 倉田陽加, 金谷有紗, 石川寛, 篠道弘, 戸高明子 Journal of Japanese Society of Pharmaceutical Oncology 25: 33-33, 2022.

	P-034. Effect of the concomitant drug giving it to the effect of treatment of the immune checkpoint inhibitor in patients with stomach cancer 渡邊一史, 小室雅人, 増田純一, 小島康志, 山田和彦, 寺門浩之 Journal of Japanese Society of Pharmaceutical Oncology 25: 34-34, 2022.

	P-035. Use stocktaking of the molecular target medicine in the primary treatment for unresectable progress recurrence colon cancer 海野祥生, 高木淳也, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 25: 35-35, 2022.

	P-036. Examination of the risk factor to be exacerbated by ramucirumab administration more than proteinuria 2+ 高田昂輔, 平出美紀, 縄田修一, 若村邦彦, 松倉聡, 北見明彦, 渡邊徹 Journal of Japanese Society of Pharmaceutical Oncology 25: 36-36, 2022.

	P-037. Look at the rear about infusion reaction at Obinutuzumab introduction; mark investigation 松下尚弘, 桑崎綾子, 原友子, 古賀清弘, 田中早穂子, 町田梨絵子, 石田早絵, 黒木吟美, 石丸隆之, 野中敏治 Journal of Japanese Society of Pharmaceutical Oncology 25: 37-37, 2022.

	P-038. Examination of the overall survival in the case that resulted in renal failure with an immune checkpoint inhibitor: Rearward observational study 久保田将史, 小島千佳, 田中里佳, 長沼篤, 蟻川勝 Journal of Japanese Society of Pharmaceutical Oncology 25: 38-38, 2022.

	P-039. Examination about the safety of the short hydration method in the urothelium cancer GC therapy 山本恵梨香, 寺島聡子, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 25: 39-39, 2022.

	P-040. Investigation of the immune-mediated adverse event with the immune check inhibitor 前田美紀, 寺島聡子, 加藤一郎 Journal of Japanese Society of Pharmaceutical Oncology 25: 40-40, 2022.

	P-041. Investigation about the blood sugar determination in patients with pancreatic cancer during cancer medical treatment 丸山真一, 木田有里子, 永瀬怜司, 太田恵, 菅野浩 Journal of Japanese Society of Pharmaceutical Oncology 25: 41-41, 2022.

	P-042. Fact-finding about the steroid duration of treatment for immune-mediated adverse event (irAE) with the immune checkpoint inhibitor 中田千博, 川澄賢司, 川崎敏克 Journal of Japanese Society of Pharmaceutical Oncology 25: 42-42, 2022.

	P-043. Administration time shortening in the ramucirumab and examination about the adverse event expression ratio 水馬佑輔, 神原史織, 尾高登美枝, 野村瑞, 岩村高弘, 森光保武, 藤井秀一 Journal of Japanese Society of Pharmaceutical Oncology 25: 43-43, 2022.

	P-044. Fact-finding of the onset of eruption in the Gemcitabine+nab-Paclitaxel therapy 香取史菜, 丸山真一, 太田恵, 永瀬怜司, 菅野浩 Journal of Japanese Society of Pharmaceutical Oncology 25: 44-44, 2022.

	P-045. Examination about the infusion reaction protective efficacy of Dexamethasone with the Pertuzumab, Trastuzumab, Docetaxel combination therapy 安積奈々美, 稲田佑亮, 黒須智博, 立石朝子, 柳澤友希, 貞重実央, 畠山恵美, 望月梨沙子, 山下敦志 Journal of Japanese Society of Pharmaceutical Oncology 25: 45-45, 2022.

	P-046. The investigation that the continuation intervention of the pharmacist contributes to a treatment successful execution rate of adjuvant chemotherapy (S1+DOC) after the stomach cancer technique 畠山朋樹, 石森雅人, 佐藤麻理, 岩井峻一, 郡山佳貴, 福田稔 Journal of Japanese Society of Pharmaceutical Oncology 25: 46-46, 2022.

	P-047. Examination of the genetic factor associated with the effectiveness with the SP therapy in patients with progress gastric cancer and the neutropenia 澤昇平, 淵本理沙, 辻大樹, 山本圭祐, 佐原由莉, 瀧口晶子, 古橋侑樹, 松川陽央, 都甲海, 荒川大輔, 中道秀徳, 伊藤邦彦, 矢部勝茂 Journal of Japanese Society of Pharmaceutical Oncology 25: 47-47, 2022.

P-047. Examination of the genetic factor associated with the effectiveness with the SP therapy in patients with progress gastric cancer and the neutropenia
澤昇平, 淵本理沙, 辻大樹, 山本圭祐, 佐原由莉, 瀧口晶子, 古橋侑樹, 松川陽央, 都甲海, 荒川大輔, 中道秀徳, 伊藤邦彦, 矢部勝茂
Journal of Japanese Society of Pharmaceutical Oncology 25: 47-47, 2022.

	P-048. Survey on the use of anamorelin hydrochloride in our hospital 東里奈, 田中亮, 丸山直岳, 別府博仁, 土井敏行 Journal of Japanese Society of Pharmaceutical Oncology 25: 48-48, 2022.

	P-049. Examination of frequencies of the infusion reaction with the antiHER2 medicine for patients with breast cancer in the Tokyo Dental College Ichikawa General Hospital and the actions to be taken 加賀麻友美, 門田佳子 Journal of Japanese Society of Pharmaceutical Oncology 25: 49-49, 2022.

	P-050. Drug costs by the supportive care standardization of the cancer chemotherapy regimen and intravenous feeding on-duty hours reduction effect 木村直孝, 渡邊裕之, 入江紘加, 村上賢次, 早坂大, 宅和真由美 Journal of Japanese Society of Pharmaceutical Oncology 25: 50-50, 2022.

	P-051. Search of the risk factor about the blood toxicity expression of RAM+PTX therapy and the RAM+nab-PTX therapy in the progress recurrent gastric cancer 大澤美紗, 中條倫成, 多久佳成, 内野智信, 大澤隆志, 賀川義之, 鈴木貴也 Journal of Japanese Society of Pharmaceutical Oncology 25: 51-51, 2022.

	P-052. Examination about the treatment by Palbociclib weight loss start neutropenia to develop early 鈴木訓史, 小林美奈子, 東敬太, 内藤義博, 渡邉隆紀 Journal of Japanese Society of Pharmaceutical Oncology 25: 52-52, 2022.

	P-053. After the operation of elderly people colon cancer StageIII in our hospital adjuvant chemotherapy - guidelines and real - 相澤康子 Journal of Japanese Society of Pharmaceutical Oncology 25: 53-53, 2022.

	P-054. Fact-finding about the dose of the levothyroxine for the hypothyroidism of the immune checkpoint inhibitor 小林美奈子, 梅内実穂, 東敬太, 鈴木訓史, 木皿重樹, 内藤義博 Journal of Japanese Society of Pharmaceutical Oncology 25: 54-54, 2022.

	P-055. Rearward examination for the dose adequacy of CBDCA of the TC therapy in gynecologic tumor 草野淳一, 塚本啓貴, 矢吹優, 山本龍世, 小澤有輝, 山田緑, 吉田理, 荒瀬透, 杉山健太郎, 林誠一 Journal of Japanese Society of Pharmaceutical Oncology 25: 55-55, 2022.

	P-056. Efforts and result about drug vial optimization to be able to put for oil xanthan gum (R) infusion 小原悠, 太田智博, 井上莉香, 佐々木寿子, 田村和敬, 厚田幸一郎 Journal of Japanese Society of Pharmaceutical Oncology 25: 56-56, 2022.

	P-057. The current situation investigation about CARG score and the anticancer agent dose 伊佐治麻里子, 日下部鮎子, 桑山果織, 村上梨沙子, 前田直大, 橋本哲郎, 白井博 Journal of Japanese Society of Pharmaceutical Oncology 25: 57-57, 2022.

	P-058. About efforts for the expression prevention of the infusion reaction with the daratumumab intravenous feeding 水岡大策, 山口佳津騎, 越野優希, 田中裕章, 小坂信二 Journal of Japanese Society of Pharmaceutical Oncology 25: 58-58, 2022.

	P-059. Investigation about thyroid gland, the adrenal dysfunction in the use of immune checkpoint inhibitor patients 永井海舟, 新福菜月, 山下亜由子, 藤宮佳菜, 武富瑞希, 本田梨紗, 益田宏代, 合田明博 Journal of Japanese Society of Pharmaceutical Oncology 25: 59-59, 2022.

P-060. Efforts of Onco-Nephrology unit for urinalysis adequacy in the use of antiVEGF medicine patients
三羽伸明, 池見泰明, 猪熊容子, 山本将太, 鈴木嘉子, 野口葉子, 高橋悠, 中村友紀, 増田崇, 北田徳昭, 中川俊作, 米澤淳, 船越太郎, 堀松高博, 山本伸也, 松原雄, 柳田素子, 武藤学, 松原和夫, 寺田智祐
Journal of Japanese Society of Pharmaceutical Oncology 25: 60-60, 2022.

	P-061. Examination of the factor affecting the effectiveness of the immune checkpoint inhibitor 東敬太, 小林美奈子, 猪俣結衣, 唐芳浩太, 鈴木訓史, 内藤義博 Journal of Japanese Society of Pharmaceutical Oncology 25: 61-61, 2022.

	P-062. Is the Osimertinib by lung cancer first treatment usable in the elderly people safely? 渡邉はるか, 高橋紗英子 Journal of Japanese Society of Pharmaceutical Oncology 25: 62-62, 2022.

	P-063. Effect of the gastric-acid secretion inhibitor to give to opioid-induced constipation protective efficacy with magnesium oxide on patients with non-chronic constipation 石神友介, 高橋克之, 高橋正也, 中村安孝 Journal of Japanese Society of Pharmaceutical Oncology 25: 63-63, 2022.

	P-064. Examination of the validity of the simplified irAE check list 太田俊哉, 岸川友紀, 君塚舜, 坂口めぐみ, 鈴木結利花, 彌冨恵, 大竹満博 Journal of Japanese Society of Pharmaceutical Oncology 25: 64-64, 2022.

	P-065. Examination of the hypotension risk factor in the 5-aminolevulinic acid (5-ALA) remedy 西田未奈, 槙原克也, 松村友和 Journal of Japanese Society of Pharmaceutical Oncology 25: 65-65, 2022.

	P-066. The case that was given antibody cocktail therapy to the patients whom COVID-19 developed in during breast cancer chemotherapy 春原龍矢, 川田亮 Journal of Japanese Society of Pharmaceutical Oncology 25: 66-66, 2022.

	P-067. Association between hands and feet skin test and liver residual function by the sorafenib for the unresectable hepatocellular carcinoma 黒部健太郎, 貞嶋栄司, 草葉一友 Journal of Japanese Society of Pharmaceutical Oncology 25: 67-67, 2022.

	P-068. Safe examination in ramucirumab + paclitaxel therapy and the ramucirumab + albumin suspension type paclitaxel therapy 朝倉幹己, 藤林遼, 鈴木直哉, 菊地義明, 山田将悟, 田中耕太, 橋本咲季, 菊地亮朗, 藤田果那, 庄崎沙耶, 山本翔太, 前川英輝, 高橋誠, 青田忠博 Journal of Japanese Society of Pharmaceutical Oncology 25: 68-68, 2022.

	P-069. Report of the Infusion related reaction expression situation at the trastuzumab Biosimilar initial administration after the trastuzumab precedence product introduction 岩村高弘, 森光保武, 藤井秀一 Journal of Japanese Society of Pharmaceutical Oncology 25: 69-69, 2022.

	P-070. The current situation report for the appearance care and future problem (the second report) 佐藤麻理, 石森雅人, 畠山朋樹, 岩井峻一, 郡山佳貴, 宮崎美子, 福田稔 Journal of Japanese Society of Pharmaceutical Oncology 25: 70-70, 2022.

	P-071. The case that increased tension by the dexamethasone of the supportive care medicine was suspected in 吉田勝好, 安木早紀, 田原明子, 服部晋司, 郷原学 Journal of Japanese Society of Pharmaceutical Oncology 25: 71-71, 2022.

	P-072. Example that we gave FOLFOX therapy because of impaired renal function for patients with old cancer of the esophagus, and CR was obtained 緑川文恵, 松井綾香, 平井梨紗子, 奥山和哉, 古澤章秀, 関根均, 星川竜彦 Journal of Japanese Society of Pharmaceutical Oncology 25: 72-72, 2022.

	P-073. 1 case that was able to affect side effect management in the Cabozantinib 谷口明展 Journal of Japanese Society of Pharmaceutical Oncology 25: 73-73, 2022.

	P-074. One case of appendix cancer which led to early detection, treatment of the phlebothrombus of lower extremities by the intervention of the pharmacist 南有里, 中村俊貴, 左右田和枝, 松原肇 Journal of Japanese Society of Pharmaceutical Oncology 25: 74-74, 2022.

	P-075. About the expression situation and the therapeutic drug of hypersensitivity at the docetaxel administration and edema 三橋平, 宇井可奈枝, 高坂暢, 加瀬博貴, 斎藤恭正 Journal of Japanese Society of Pharmaceutical Oncology 25: 75-75, 2022.

	P-076. It is ... for role - pharmacist outpatient department of the pharmacist at the regorafenib medication to an outpatient 松下雅昭 Journal of Japanese Society of Pharmaceutical Oncology 25: 76-76, 2022.

	P-077. The case that led to the early detection of the adverse event by the continuous telephone follow-up of patients receiving immune checkpoint inhibitor 三上寿世 Journal of Japanese Society of Pharmaceutical Oncology 25: 77-77, 2022.

	P-078. 2 cases that developed adrenal insufficiency during ICI combination treatment 宮永和美, 北出紘規, 西野正義, 中井正治, 岡本拓也 Journal of Japanese Society of Pharmaceutical Oncology 25: 78-78, 2022.

	P-079. One patient who gave peg filgrastim after three days of dexrazoxane administration, and showed protraction of myelosuppression subsequently 佐野阿耶, 矢口あゆみ, 齊藤有希, 小柴聖史, 佐藤邦義, 荒川隆太郎 Journal of Japanese Society of Pharmaceutical Oncology 25: 79-79, 2022.

	P-080. One patient who was able to continue treatment by a pharmacist having intervened in decision aiding 虻川詩希子, 浪岡恭子, 鈴木郁子, 大石晋 Journal of Japanese Society of Pharmaceutical Oncology 25: 80-80, 2022.

	P-081. Investigation of the use situation and the side effect expression in the nab-PTX therapy of patients with our hospital gastrointestinal carcinoma 吉村美果, 寺尾勇紀, 山関智恵, 三浦毅 Journal of Japanese Society of Pharmaceutical Oncology 25: 81-81, 2022.

	P-082. Role of the drugstore pharmacist in the side effect monitoring of foreign chemotherapy patients 鈴木佑太朗, 佐藤絵馬, 永野悠馬, 前田守, 赤木佐千子, 長谷川佳孝, 月岡良太, 大石美也 Journal of Japanese Society of Pharmaceutical Oncology 25: 82-82, 2022.

	P-083. The case that presented vocal disorder in the digestive organ cancer chemotherapy 伊地知由樹, 飯村洋平, 阿彦友佳, 田邊太郎, 釣田義一郎, 愛甲丞, 志田大, 黒田誠一郎 Journal of Japanese Society of Pharmaceutical Oncology 25: 83-83, 2022.

	P-084. The breast cancer that suffered from a dosage of the zoledronic acid accompanied with the Abemaciclib start, 1 case of patients with metastases to bone 尾形美絵, 近藤和宏, 羽生智宏, 新関みどり, 長澤欣弘, 瀧内瑛輔, 中村槙一郎, 田村和彦 Journal of Japanese Society of Pharmaceutical Oncology 25: 84-84, 2022.

	P-085. 1 case that was given Osimertinib and chemotherapy for overlap lung cancer at the same time 徳島英明, 山口竜司, 児玉沙奈恵, 和田依子, 佐々木好美, 樋口美奈子, 檜山智子 Journal of Japanese Society of Pharmaceutical Oncology 25: 85-85, 2022.

P-086. The dermatopathy 1 case that it is poor in the control that we experienced by Bevacizumab + Trifluridine/Tipiracil therapy in colon cancer treatment
山田将悟, 鈴木直哉, 橋本咲季, 菊地亮朗, 朝倉幹己, 藤田果那, 田中耕太, 庄崎沙耶, 山本翔太, 前川英輝, 菊地義明, 藤林遼, 高橋誠, 青田忠博
Journal of Japanese Society of Pharmaceutical Oncology 25: 86-86, 2022.

	P-087. The case that became available for long-term treatment by a regorafenib weight loss administration start 竹内勉, 矢倉利香, 片岡優子, 立山裕美子, 松浦貴世, 堀切雅哉, 森利恵 Journal of Japanese Society of Pharmaceutical Oncology 25: 87-87, 2022.

	P-088. Example that the follow-up with the telephone to the patients who started XELOX therapy was useful 大沢光平, 北御門智世, 馬場隆彰, 北村哲, 川口向司, 中井雅智, 木村礼志 Journal of Japanese Society of Pharmaceutical Oncology 25: 88-88, 2022.

	P-089. Three cases in which leucovorin rescue minimized oral mucosal toxicity of pralatrexate 金子憲太郎, 川口文誉, 野口果歩, 杉本誠, 豊田茂雄, 土井路子 Journal of Japanese Society of Pharmaceutical Oncology 25: 89-89, 2022.

	P-090. 1 case of the follow-up for the digestive organ symptom of Erlotinib and the lansoprazole remedy patients 小畑志保, 中村暢彦, 吉田勝好, 吉田知香, 楠本正明 Journal of Japanese Society of Pharmaceutical Oncology 25: 90-90, 2022.

	P-091. An example of the nivolumab-related colitis in patients with gastric cancer with the existing ulcerative colitis 小川竜徳, 四十物由香, 八木澤昴大, 岩山竜大, 平井信二, 田村明広 Journal of Japanese Society of Pharmaceutical Oncology 25: 91-91, 2022.

	P-092. One case that was able to accomplish treatment by a change of the supportive care in the BEP therapy for testicular tumors 増田詩子, 赤井喜一, 石田朋己, 塩見のぞみ, 四方友也, 寺田真弓, 大島辰也, 真下智行, 外賀紗織, 太田翔一, 林田和久, 中西弘之, 杉田直哉 Journal of Japanese Society of Pharmaceutical Oncology 25: 92-92, 2022.

	P-093. One patient who developed hypoadrenalism from the end of the Pembrolizumab + Axitinib combination therapy for renal cell carcinoma after the long-term course 工藤みなみ, 森本真宗, 竹下英毅, 近藤正巳 Journal of Japanese Society of Pharmaceutical Oncology 25: 93-93, 2022.

	P-094. The current situation of the elderly people cancer chemotherapy in our hospital and safe evaluation 小倉敬史, 松田沙貴子, 寺本奈生, 大舘祐佳, 花屋志織, 星野恵, 山本伊純, 北岡晃 Journal of Japanese Society of Pharmaceutical Oncology 25: 94-94, 2022.

	P-095. Introduction of the prophylactic skin care check sheet for the dermatopathy with the anticancer medicine 地引勝, 鈴木大介, 藤井敦子, 矢口いづみ Journal of Japanese Society of Pharmaceutical Oncology 25: 95-95, 2022.

	P-096. About the intervention of the case with suspected side effect allied adverse event of the immune checkpoint inhibitor of immunity 田中智枝 Journal of Japanese Society of Pharmaceutical Oncology 25: 96-96, 2022.

	P-097. About the side effect follow-up in the health insurance pharmacy for the oral molecular target medicine remedy patients 朝倉美紗 Journal of Japanese Society of Pharmaceutical Oncology 25: 97-97, 2022.

	P-098. One case that chemotherapy-induced peripheral neuropathy improved 浮田理沙, 甲谷章, 臼井麻郁子, 照瀬美紗, 谷村紀代子, 菊井利伸, 秋吉由利子 Journal of Japanese Society of Pharmaceutical Oncology 25: 98-98, 2022.

	P-099. One case that it showed rheumatoid arthritis exacerbation after the Pembrolizumab combination therapy enforcement for recurrent case after the lung adenocarcinoma technique with the rheumatoid arthritis of the low disease activity 鈴木和磨, 森本真宗, 大矢浩之, 桑原由樹, 近藤恒夫, 近藤正巳 Journal of Japanese Society of Pharmaceutical Oncology 25: 99-99, 2022.

	P-100. One case of the progress gastric cancer with suspected tumor lysis syndrome with the S-1 monotherapy 谷池仁志, 五十川達哉, 荒金裕敏, 河野祥三 Journal of Japanese Society of Pharmaceutical Oncology 25: 100-100, 2022.

	P-101. One patient who introduced the short hydration method in cisplatin treated patients 八木洋介, 石王亮次, 巌城まなみ, 松田和也, 松澤康博 Journal of Japanese Society of Pharmaceutical Oncology 25: 101-101, 2022.

	P-102. An example of the mFOLFOX6 + BEV therapy in haemodialysis patients 大竹浩紀, 平山啓朗, 小澤直登, 栗原真之介, 山口実佐子, 大屋さおり, 臼田江梨, 池嶋晴美, 門野政義, 原佳津行, 山崎秀久 Journal of Japanese Society of Pharmaceutical Oncology 25: 102-102, 2022.

	P-103. Example that accepted transient visual field disorders for each oxaliplatin administration 川島悠吾, 宗本尚子, 村嶋彩加, 鳥居奈央, 工藤道弘, 福田賢一郎, 清水義博, 松本圭司 Journal of Japanese Society of Pharmaceutical Oncology 25: 103-103, 2022.

	P-104. Usefulness of the desensitization for patients with Carboplatin hypersensitivity in our hospital 川端志津, 松元美香, 大谷道輝, 河野勤 Journal of Japanese Society of Pharmaceutical Oncology 25: 104-104, 2022.

	P-105. One case that was able to accomplish the supportive care to the chemo brain suspicion patients by telephone follow-up enforcement 阿部華奈, 高木恵梨, 上田悠, 吉留実慧子, 高子優子, 若松雄太, 細見真世, 澁谷奈穂, 近藤万友美, 吉岡睦展 Journal of Japanese Society of Pharmaceutical Oncology 25: 105-105, 2022.

	P-106. A case of erythema nodosum eruption during combination therapy with encorafenib, binimetinib, and cetuximab 林克剛, 土屋雅美, 内田敬, 猪岡京子, 大塚和令, 村川康子, 西條嘉代子 Journal of Japanese Society of Pharmaceutical Oncology 25: 106-106, 2022.

	P-108. Intervention case by the telephone follow-up to patients with colon cancer during the mFOLFOX6 + Bev therapy enforcement 河端明子 Journal of Japanese Society of Pharmaceutical Oncology 25: 108-108, 2022.

	P-109. One case that developed hypersensitivity during nedaplatin administration for cervical cancer, but was a readministration possibility 森貴世考, 森本真宗, 大矢浩之, 木崎雄一朗, 魚谷隆弘, 近藤正巳 Journal of Japanese Society of Pharmaceutical Oncology 25: 109-109, 2022.

	P-110. One case that intervened in vascular pain measures by dacarbazine (DTIC) 國本佳香, 木山弘毅, 津崎晃一, 須山孝宏, 安達妙 Journal of Japanese Society of Pharmaceutical Oncology 25: 110-110, 2022.

	P-111. Have a drugstore pharmacist for a hot flash during breast cancer treatment 宮田香織, 藤田あゆみ, 杉浦伸哉, 渡部誠士 Journal of Japanese Society of Pharmaceutical Oncology 25: 111-111, 2022.

	P-112. One case that was able to support with commercial drug loperamide preparation for diarrhea during Osimertinib remedy 細田宗良 Journal of Japanese Society of Pharmaceutical Oncology 25: 112-112, 2022.

	P-113. One case that was able to notice that a health food intake influenced treatment of the essential thrombocythaemia by the interview of the health insurance pharmacy pharmacist 山本雅裕, 藤田あゆみ, 杉浦伸哉, 杉浦克典 Journal of Japanese Society of Pharmaceutical Oncology 25: 113-113, 2022.

	P-114. One case of hepatocytes cancer that stable high blood pressure was rapidly exacerbated by Atezolizumab/bevacizumab combination therapy start by medical therapy 白鳥瞳, 新井聡子, 濱野愛里, 中野諒太, 小野村理抄, 軍司剛宏 Journal of Japanese Society of Pharmaceutical Oncology 25: 114-114, 2022.

	P-115. 1 case that was able to sense an olanzapine-induced epileptic seizure by a telephone follow-up 藤井康之 Journal of Japanese Society of Pharmaceutical Oncology 25: 115-115, 2022.

	P-116. A case of opioid rotation from methadone to hydromorphone injection 屋敷大輔, 中村杏果, 森永崇史, 池沢若菜, 田中恭人, 豊留麻衣, 北園幸大, 中野一馬, 山本梢, 淵脇ゆかり, 徳丸章佳, 長ヶ原琢磨, 荻尾夕起子, 濱田琴巳, 岸本真 Journal of Japanese Society of Pharmaceutical Oncology 25: 116-116, 2022.

	P-117. One case that Paclitaxel + Bevacizumab therapy was effective for breast cancer bone marrow carcinosis 中野悠馬, 岩本美樹, 村本優樹, 品田似奈, 加藤水月, 関口朝美, 津留未来, 原田恵, 百武綾香, 柳田義一 Journal of Japanese Society of Pharmaceutical Oncology 25: 117-117, 2022.

	P-118. About the dosage of the mirogabalin for chemotherapy-induced peripheral neuropathy in the decreased renal function patients 清水敦也, 遠藤亮祐, 山佳織, 佐藤秀紀, 長谷川功, 鶴間哲弘 Journal of Japanese Society of Pharmaceutical Oncology 25: 118-118, 2022.

P-119. One patient who was reducing an oxycodone sustained release drug, and withdrawal sign appeared, but succeeded in coexistence support
菊地義明, 鈴木直哉, 山本翔太, 田中耕太, 橋本咲季, 菊地亮朗, 朝倉幹己, 藤田果那, 庄崎沙耶, 山田将悟, 前川英輝, 藤林遼, 高橋誠, 青田忠博
Journal of Japanese Society of Pharmaceutical Oncology 25: 119-119, 2022.

	P-120. To offer best cancer treatment to the area by reliable security 小野貴光 Journal of Japanese Society of Pharmaceutical Oncology 25: 120-120, 2022.

P-121. When shall do medication follow, the call to patients with first cancer; ... retching, efforts ... at the specialty medical institution cooperation drugstore mainly on vomiting
藪田碧, 白井雅博, 前原直美, 三田村友子, 松田裕紀子, 野田澤麗子, 甲斐和代, 安藤千夏子, 前川絵莉香, 猪飼千佳代, 松本広美
Journal of Japanese Society of Pharmaceutical Oncology 25: 121-121, 2022.

	P-122. Examination from 1 case that experienced at-home end-of-life care from palliative care system - outpatient department chemotherapy to patients with cancer in the specialized medical institution cooperation drugstore 野尻悠斗, 柴田賢三 Journal of Japanese Society of Pharmaceutical Oncology 25: 122-122, 2022.

	P-123. Content analysis of the doubt inquiry example about the cancer chemotherapy in the foreign chemotherapy room 平川寛之, 齊藤裕子, 倉田奈央子, 山内雅仁, 高橋将典, 森由佳里, 塩澤誠, 岡田浩司 Journal of Japanese Society of Pharmaceutical Oncology 25: 123-123, 2022.

	P-124. Examination of exposure measures at the anticancer agent bladder infusion therapy in our hospital 中出恵里奈, 有原大貴, 間宮公教, 宮澤憲治, 秋山哲平 Journal of Japanese Society of Pharmaceutical Oncology 25: 124-124, 2022.

	P-125. It is efforts ... for the standardization of ... regimen evaluation for enforcement of the appropriate and safe cancer chemotherapy 渡瀬美登里, 大森淳史, 堂薗吉彬, 柏田匡広, 坂本欣直 Journal of Japanese Society of Pharmaceutical Oncology 25: 125-125, 2022.

	P-126. Efforts to the pharmaceutical inspection standardization of the cancer chemotherapy regimen using the check sheet 田代匠, 青野智恵美, 彦坂麻美, 内野達宏, 高木亮 Journal of Japanese Society of Pharmaceutical Oncology 25: 126-126, 2022.

	P-127. A change of the cost & preparation time by the closed system anesthesia drug transportation system full-scale introduction and questionary survey to a healthcare worker 原田優, 橋口宏司, 佐伯朋也, 横山敦, 中島研 Journal of Japanese Society of Pharmaceutical Oncology 25: 127-127, 2022.

	P-128. Examination about the effect of a risk factor and the renin-angiotensin system inhibitor of the onset of proteinuria by the ramucirumab 坂本和央, 原祐, 飯田美紅, 若松綾華, 荒川桃子, 友寄旬, 村中一大, 須藤美穂子, 鈴木千波, 小原秀治, 柴波明男, 樋浦一哉 Journal of Japanese Society of Pharmaceutical Oncology 25: 128-128, 2022.

	P-129. Basic study ... of toxic extreme time difference ... sensitivity time difference of the 6-mercaptopurine 宮澤正幸, 金子正裕, 宮本航大, 照井楓花, 桂川真一, 横田理, 吉岡弘毅, 三浦伸彦 Journal of Japanese Society of Pharmaceutical Oncology 25: 129-129, 2022.

	P-130. An evaluation after the PBPM introduction in blood, the tumor internal medicine and the problem 園部あみ, 湯山聡, 伊勢崎竜也, 舟越亮寛 Journal of Japanese Society of Pharmaceutical Oncology 25: 130-130, 2022.

	P-131. A study on usability and economy of the portable continuous injector Torefuser (R) type T 佐藤拓行, 辻峻, 鈴木亜沙美, 天野敬大, 野口宣之 Journal of Japanese Society of Pharmaceutical Oncology 25: 131-131, 2022.

	P-132. Anticancer medicine exposure measures to work on in PDCA cycle 後藤梓沙, 杉野善彦, 大島有美子, 桜田宏明 Journal of Japanese Society of Pharmaceutical Oncology 25: 132-132, 2022.

P-133. New efforts of the clinical experimental medicine management using the QR cord indication
新藤実香, 浅野智央, 前田誠, 平山久美子, 小林奈津美, 仁科満美, 上島亜紀, 大野由香子, 今泉克明, 久保晶子, 渡邉真緒, 石川光信, 橋本浩伸, 赤木徹, 齋藤義正, 古川哲也
Journal of Japanese Society of Pharmaceutical Oncology 25: 133-133, 2022.

	P-134. Addition of the medical examination item for the person of anticancer agent preparation 佐々木紀彰, 唯間和博, 三橋寿々乃, 篠原健, 古元俊徳 Journal of Japanese Society of Pharmaceutical Oncology 25: 134-134, 2022.

	P-135. Establishment of a cooperative system with doctors and registered dietitians for guidance on the introduction of VENCLEXTA 濱中悠賀, 栗原りか, 佐藤亜希穂, 小池美紀, 高橋正弥, 新行内健一, 海老原卓志, 松本守生, 金井貴充 Journal of Japanese Society of Pharmaceutical Oncology 25: 135-135, 2022.

	P-136. About efforts of the anticancer agent mixing in the corona evil 高木明子, 渡慶次星, 津田優里香, 高本裕子, 古川莉彩, 安永美月, 長島裕樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 136-136, 2022.

P-137. Examination about the PPE reduction effect of the identifier by confirming remote with the quantity to weigh using "an anticancer medicine preparation camera support system"
岸本真, 中村杏果, 森永崇史, 池沢若菜, 田中恭人, 豊留麻衣, 北園幸大, 中野一馬, 山本梢, 屋敷大輔, 淵脇ゆかり, 徳丸章佳, 長ケ原琢磨, 荻尾夕起子, 児玉友和
Journal of Japanese Society of Pharmaceutical Oncology 25: 137-137, 2022.

P-138. Efforts of the pharmacist for an investigation and the reactivation prevention of the hepatitis B reactivation screening enforcement situation before the chemotherapy enforcement in our hospital
嶋田紘也, 木村美貴, 阿部瑛子, 吉田ミチル, 藤田美涛, 大橋啓子, 遠藤修司, 平岩知子, 久武純一, 後藤亨
Journal of Japanese Society of Pharmaceutical Oncology 25: 138-138, 2022.

	P-139. Contribution of the pharmacist by the PBPM enforcement for antiVEGF antibody medicine proper use 倉本響, 沢田佳祐, 出口桃子, 清水愛, 山本浩之, 中谷丈之, 河野修治 Journal of Japanese Society of Pharmaceutical Oncology 25: 139-139, 2022.

	P-140. Comparison of the preparation time by the pemetrexed infusion liquid introduction 奥山裕子, 南和志, 石倉一樹, 田村健悦 Journal of Japanese Society of Pharmaceutical Oncology 25: 140-140, 2022.

	P-141. Examination about the simple suspension method application advisability of the internal use anticancer agent 草壁咲苗恵, 安部智哉, 直井美萌, 大塚公庸 Journal of Japanese Society of Pharmaceutical Oncology 25: 141-141, 2022.

	P-142. Fact-finding of the truncation of the dose of anticancer medicine in the breast cancer medical therapy and the antiHER2 medicine 山本皓介, 越野勝博, 堀口裕美, 新宮秀昭, 土淵尚也 Journal of Japanese Society of Pharmaceutical Oncology 25: 142-142, 2022.

	P-143. About the nephrotoxic expression of cisplatin situation in patients with childhood cancer 研真梨子, 池啓伸, 藤原康浩, 垣尾尚美, 合田泰志 Journal of Japanese Society of Pharmaceutical Oncology 25: 143-143, 2022.

	P-144. Evaluation of efforts and the usefulness for the outside regimen system introduction accompanied with the hospital move 安部圭紀, 五十嵐文, 辻茉莉香, 溝口明子, 五十嵐俊, 高橋賢成 Journal of Japanese Society of Pharmaceutical Oncology 25: 144-144, 2022.

	P-145. Relation of the pharmacist in the examination for oncogene panel in the Kyushu cancer center 衛藤智章, 仲田浩成, 高城沙也香, 江崎泰斗, 清水裕彰 Journal of Japanese Society of Pharmaceutical Oncology 25: 145-145, 2022.

	P-146. The oral anticancer agent regimen check system construction in the outside Parliament prescription and usefulness evaluation of the medical economics 吉田弘樹, 鈴木雅人, 牧原明秀, 三屋良太, 高原悠子, 木全司 Journal of Japanese Society of Pharmaceutical Oncology 25: 146-146, 2022.

	P-147. Comparative study about the effect that we gave to the medication counseling time at the drugstore by the revised medicine machine method enforcement in 2020 長沼未加, 島貫英二 Journal of Japanese Society of Pharmaceutical Oncology 25: 147-147, 2022.

	P-148. The case that led to early correspondence early detection of heart failure through Durvalumab by utilizing telephone medication support (R) and a tracing report 堀龍太郎, 武田照幸, 山崎友里絵, 田中寿和, 長沼敬子, 木下隆市, 染谷光洋, 宮岡勝弘, 谷口亮央, 中島史雄 Journal of Japanese Society of Pharmaceutical Oncology 25: 148-148, 2022.

	P-149. Attitude survey for the cancer practice Hospital in Hatsukaichi district and Onomichi district cooperation training of the health insurance pharmacy pharmacist 平井俊明, 栗原晋太郎, 礒貝明彦, 橋本佳浩, 堀川俊二, 渡邊英晶, 山下大介, 友滝恵子, 安保圭介 Journal of Japanese Society of Pharmaceutical Oncology 25: 149-149, 2022.

	P-150. About calculation and efforts of the cooperation full addition 内藤梨奈, 齋藤菜奈, 小松春佳, 春田貴史, 江藤壮志, 林恵子, 林みどり, 保坂麻弥 Journal of Japanese Society of Pharmaceutical Oncology 25: 150-150, 2022.

	P-151. Examination of the effect that the intervention of the palliative care team gives to the painful score of patients with cancer 間美和, 山中紗弥花, 末長芽以, 藤本愛理, 木村滋, 花田聖典, 川俣洋生, 橋本雅司 Journal of Japanese Society of Pharmaceutical Oncology 25: 151-151, 2022.

	P-152. Effect to the immune-mediated adverse event management of the education hospitalization clinical path in the immune checkpoint inhibitor introduction patients 山口真実, 工藤慶太, 鉾立えり子, 畑中朋子, 佐々木祐太, 山西香織, 田路章博, 粉川俊則 Journal of Japanese Society of Pharmaceutical Oncology 25: 152-152, 2022.

	P-153. The thing which we saw through medicine medicine cooperation from the cooperation full addition over there 内田美伽, 酒井鉄平, 相川晴彦, 嶋田烈, 上野正夫 Journal of Japanese Society of Pharmaceutical Oncology 25: 153-153, 2022.

	P-154. The medicine medicine cooperation current situation investigation of the local cancer practice cooperation base Hospital and local health insurance drugstore for regional alliances enhancement 大崎真美, 疋田絵梨, 鈴木礼乃, 秦哲磨, 村上菜月, 黒木あかね, 浦山泰典, 安武夫, 城田幹生 Journal of Japanese Society of Pharmaceutical Oncology 25: 154-154, 2022.

	P-155. Significance of the workshop holding with the pharmacy service under health insurance drugstore about the system reinforcement of the medicine medicine cooperation 川村真理恵, 酒井由希子, 大野豊 Journal of Japanese Society of Pharmaceutical Oncology 25: 155-155, 2022.

	P-156. It is examination about the usefulness of the pharmacist outpatient department for the side effect of the UFT/LV therapy in the adjuvant chemotherapy after the colon cancer technique 山本龍世, 小澤有輝, 草野淳一, 矢吹優, 吉田理, 松田睦史, 林誠一 Journal of Japanese Society of Pharmaceutical Oncology 25: 156-156, 2022.

	P-157. About efforts to foreign cancer chemotherapy in our hospital 藤田淳志, 米北浩人, 津野侑子, 中村英治 Journal of Japanese Society of Pharmaceutical Oncology 25: 157-157, 2022.

	P-158. Efforts of the cancer chemotherapy cooperation full addition in the Hyogo Prefectural Nishinomiya Hospital 伊勢原祐子, 藤原未都菜, 岡田悠加, 井上智恵, 日生下美紀, 西窪奈津子 Journal of Japanese Society of Pharmaceutical Oncology 25: 158-158, 2022.

	P-159. The current situation of the cooperation full addition and future problem 今川貴仁, 上岡彩佳, 小池慶彦, 日浦寿美子, 小林秀樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 159-159, 2022.

P-160. Evaluation of efforts and the patients satisfaction of the medicine medicine cooperation in the cancer chemotherapy domain in the Fukuoka University Hospital
角康隆, 長郷あかね, 柿本秀樹, 大倉野将広, 武田佳子, 五十嵐保陽, 井上竜一, 井上貴文, 真島宏太, 川田哲史, 江越菜月, 池内忠宏, 兼重晋, 神村英利
Journal of Japanese Society of Pharmaceutical Oncology 25: 160-160, 2022.

	P-161. Efforts as "the cancer practice hospital cooperation training hospital" in the Himeji medical center 西村真美, 田中麻理子, 仲野宏紀, 山本修平, 山口崇臣, 福田利明 Journal of Japanese Society of Pharmaceutical Oncology 25: 161-161, 2022.

	P-162. Efforts about the medicine medicine cooperation reinforcement in the cancer chemotherapy 河合祐輔, 福地隆康 Journal of Japanese Society of Pharmaceutical Oncology 25: 162-162, 2022.

	P-163. An evaluation and review about reporting contents accompanied with the cooperation full addition in the viewpoint of the multi-type of job 尾納明里紗, 脇田恵里, 服部昇二, 吉田知由 Journal of Japanese Society of Pharmaceutical Oncology 25: 163-163, 2022.

	P-164. Fact-finding for the drugstore authorization system according to community medical care cooperation in foreign cancer treatment and the function 本田泰斗, 櫻井洋臣, 川澄賢司, 佐々木駿一, 脇本麻美, 餅原弘樹, 飯塚雄次, 内坪敬太, 田島亮, 石原由起子, 濃沼政美, 近藤直樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 164-164, 2022.

	P-165. About an approach of the medicine medicine cooperation about irAE 大田晴香, 波部未央佳, 山口泰大, 田中将太, 渡邊小百合, 前原大輔, 大前隆弘, 石田達彦 Journal of Japanese Society of Pharmaceutical Oncology 25: 165-165, 2022.

	P-166. About tracing report introduction and medicine medicine cooperation in the foreign chemotherapy 吉澤寛朗, 高木真央, 工藤尚亨, 樅山淳子, 沖田直美, 安藤恵 Journal of Japanese Society of Pharmaceutical Oncology 25: 166-166, 2022.

	P-167. Hold medicine medicine cooperation - virtual workshop of the oral anticancer medicine which hospital pharmacist and a health insurance pharmacy pharmacist learn together; and - 杉山純子, 岩田智樹, 星野有吾, 小島昌代, 野々村寛子, 中山莉花, 川合甲祐, 久田達也, 宮崎雅之 Journal of Japanese Society of Pharmaceutical Oncology 25: 167-167, 2022.

	P-168. It is ... based on the cooperation with the health insurance pharmacy of ... inside the hospital and the Higashi-Omi demographic division of medical services about the continuous intervention effect of the pharmacist in the foreign cancer chemotherapy 植田裕美, 庄野裕志, 畝佳子 Journal of Japanese Society of Pharmaceutical Oncology 25: 168-168, 2022.

	P-169. Efforts until the authorized acquisition of the specialized medical institution cooperation drugstore and the current situation and problem 前原央奈, 角佳亮, 中澤寛仁 Journal of Japanese Society of Pharmaceutical Oncology 25: 169-169, 2022.

	P-170. Efforts to the specialized medical institution cooperation drugstore authorized acquisition and future problem 宮繁信一, 角佳亮 Journal of Japanese Society of Pharmaceutical Oncology 25: 170-170, 2022.

	P-171. Making and the current situation report of the interview sheet before encounter for the immune-mediated adverse event 吉田昌史, 土屋亜祐美, 長尾嘉真, 塚原敦子, 仲剛, 辻本佳恵, 野崎圭夏, 八木秀祐, 下村昭彦, 寺門浩之 Journal of Japanese Society of Pharmaceutical Oncology 25: 171-171, 2022.

	P-172. Competitive review of the medication counseling actual situation associated with the anticancer agent in the Onomichi district health insurance pharmacy pharmacist 栗原晋太郎, 平井俊明, 佐藤一求, 比良大輔, 橋本佳浩, 堀川俊二, 田辺ナオ, 安保圭介 Journal of Japanese Society of Pharmaceutical Oncology 25: 172-172, 2022.

	P-173. The example that intervened by a telephone follow-up of the foreign cancer chemotherapy 渡邊宣章, 仲谷誠司 Journal of Japanese Society of Pharmaceutical Oncology 25: 173-173, 2022.

P-174. Fact-finding about hospital pharmacist duties of foreign cancers treatment such as the cancer practice cooperation base Hospital, and the like and the change of the community medical care cooperation
佐々木駿一, 櫻井洋臣, 川澄賢司, 脇本麻美, 餅原弘樹, 飯塚雄次, 内坪敬太, 田島亮, 本田泰斗, 石原由起子, 濃沼政美, 近藤直樹
Journal of Japanese Society of Pharmaceutical Oncology 25: 174-174, 2022.

	P-175. 1 case of patients with unresectable progress colon cancer which we responded to through the cancer practice hospital cooperation training 白井雅博, 近野裕里, 八尾尚樹, 中村直美, 松本広美 Journal of Japanese Society of Pharmaceutical Oncology 25: 175-175, 2022.

P-176. Relation of the multi-type of job for the foreign chemotherapy room bed control duties improvement
生田和之, 寺島聡子, 海野祥生, 高木淳也, 前田美紀, 山本恵梨香, 加藤一郎, 有賀史絵, 寺林優姫, 石川美智子, 我妻真理子, 北澤諒, 嶋中ますみ, 牛島品子, 長谷川誠司, 福島忠男
Journal of Japanese Society of Pharmaceutical Oncology 25: 176-176, 2022.

	P-177. Efforts to the cooperation full addition acquisition for improvement in quality of the treatment with outpatient department anticancer agent 植田真理, 佐藤浩二, 井上咲紀, 島田敏江, 浅井真由美, 西岡達也, 藤田淳也 Journal of Japanese Society of Pharmaceutical Oncology 25: 177-177, 2022.

	P-178. There be it to strengthen local overall medicine medicine cooperation from the situation of the door front drugstore of the area cancer practice cooperation base Hospital 前田竜祐, 中村英治 Journal of Japanese Society of Pharmaceutical Oncology 25: 178-178, 2022.

	P-179. Support needs study of patients with AYA generation cancer 直井美萌, 武井大輔, 五木田茶舞, 川村眞智子, 横田治重 Journal of Japanese Society of Pharmaceutical Oncology 25: 179-179, 2022.

	P-180. Investigation about the inflection situation of the tracing report in the pharmacist outpatient department 松本光司, 石森雅人, 畠山明樹, 佐藤麻理, 郡山佳貴, 岩井俊一, 福田稔 Journal of Japanese Society of Pharmaceutical Oncology 25: 180-180, 2022.

	P-181. The adverse event management to the Osimertinib taking our hospital patients in the pharmacist outpatient department 相場悠樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 181-181, 2022.

	P-182. Making ... of the efforts - medical therapy reporting book making system of the cooperation full addition calculation in the Kitami Red Cross hospital 富田浩史, 木村彩那, 佐藤友昭, 公平弘樹, 伊藤智美, 國井みすず, 河野洋樹, 堀大, 上林実 Journal of Japanese Society of Pharmaceutical Oncology 25: 182-182, 2022.

	P-183. Needs and problem of the local joint workshop in the cancer chemotherapy 山口瑞彦, 山本圭恵, 松井諒, 遠藤正憲 Journal of Japanese Society of Pharmaceutical Oncology 25: 183-183, 2022.

	P-184. It is ... in an example by a medicine medicine cooperation program of efforts ... oral cancer medicine of the educational program in the medical a fair section of the pharmaceutical company 鍛冶屋景子, 中村絵梨, 鈴木由希子, 鈴木弓仁, 山本尚功 Journal of Japanese Society of Pharmaceutical Oncology 25: 184-184, 2022.

	P-185. Infusion precision investigation of the 5-FU dilution by the dilution apothecaries measure change of the pressurized infusion instruments 高木俊輝, 小原みずき, 川村桂子, 松本哲哉, 中村智 Journal of Japanese Society of Pharmaceutical Oncology 25: 185-185, 2022.

	P-186. The use actual situation of 0.5 mg of fentanyl citrate percutaneous absorption type preparation and safe evaluation 鍛治園誠, 佐藤晶子, 高下典子, 太田佳男, 片山英樹, 座間味義人 Journal of Japanese Society of Pharmaceutical Oncology 25: 186-186, 2022.

	P-187. The effectiveness of oral ketamine for the cancerous pain 小林慎, 姜元美, 秋山幸子, 国分秀也 Journal of Japanese Society of Pharmaceutical Oncology 25: 187-187, 2022.

P-188. The way of the pharmacist education under the COVID-19 outbreak showing from JASPO brushing up seminar 2020 participant questionnaire
土屋雅美, 寺薗英之, 牧陽介, 吉川直樹, 河原陽介, 西村佳子, 篠原佳祐, 小川大介, 森理保, 岩本義弘, 板垣文雄, 益子寛之, 米村雅人, 内田まやこ
Journal of Japanese Society of Pharmaceutical Oncology 25: 188-188, 2022.

	P-189. Anticancer medicine environmental exposure investigation in the use of closed system anesthesia drug transportation system in the isolator 渡邊紘子, 吉成徹, 赤羽正之, 鈴木健吾, 坂本鉄弥 Journal of Japanese Society of Pharmaceutical Oncology 25: 189-189, 2022.

P-190. The way of the pharmacist education under the COVID-19 outbreak showing from JASPO start-up seminar 2020 participant questionnaire
寺薗英之, 土屋雅美, 牧陽介, 吉川直樹, 河原陽介, 西村佳子, 篠原佳祐, 小川大介, 森理保, 岩本義弘, 板垣文雄, 益子寛之, 米村雅人, 内田まやこ
Journal of Japanese Society of Pharmaceutical Oncology 25: 190-190, 2022.

	P-191. Evaluation of Infusion riaction at the initial administration of Rituximab precedence product for DLBCL or biofollower product 豊川知宏, 風穴恵悦, 石橋菜摘, 奧山泰弘 Journal of Japanese Society of Pharmaceutical Oncology 25: 191-191, 2022.

	P-192. Comparison of the questionary survey that we conducted in 2014 about the medical drug medication counseling for the Onomichi district health insurance pharmacy pharmacist and 2021 佐藤一求, 平井俊明, 比良大輔, 栗原晋太郎, 橋本佳浩, 堀川俊二, 田辺ナオ, 安保圭介 Journal of Japanese Society of Pharmaceutical Oncology 25: 192-192, 2022.

	P-193. Factor search of the polypharmacy in patients with cancer of the terminal stage 荒井園枝, 藤原史江 Journal of Japanese Society of Pharmaceutical Oncology 25: 193-193, 2022.

	P-194. Does the continuation of change - chemotherapy of the physical strength index of patients who received cancer chemotherapy (G8 score) improve G8 score? ... 風岡真実, 橋本竜, 佐藤淳也 Journal of Japanese Society of Pharmaceutical Oncology 25: 194-194, 2022.

	P-195. Clinical tumor Pharmaceutical Society (JASPO) member fact-finding 2021 results report in Japan 齋藤瑛一, 畠山智明, 佐藤由美子, 前原央奈, 田中智枝, 虎石竜典, 笹津備尚, 米村雅人, 小笠原信敬 Journal of Japanese Society of Pharmaceutical Oncology 25: 195-195, 2022.

	S2-1. Impaired renal function and cancer medical therapy: interactive relationship 藤田行代志 Journal of Japanese Society of Pharmaceutical Oncology 25: 197-197, 2022.

	S2-2. The management of the cancerous pain therapeutic drug for patients with renal failure 国分秀也 Journal of Japanese Society of Pharmaceutical Oncology 25: 198-198, 2022.

	S2-3. It is taken measures a characteristic, treatment, the prevention of the malignant tumor after the kidney transplantation 藤山信弘 Journal of Japanese Society of Pharmaceutical Oncology 25: 199-199, 2022.

	S2-4. Knead on; a mission and a problem of fluoroGee: We regard the role of the specialist in kidney as a pharmacist 和田健彦 Journal of Japanese Society of Pharmaceutical Oncology 25: 200-200, 2022.

	S4-1. So that patients provide treatment for reliable security and continue it, and they accomplish it 宇田雅実 Journal of Japanese Society of Pharmaceutical Oncology 25: 201-201, 2022.

	S4-2. Hint ... from the continuous follow-up and information sharing - felicity case to patients with foreign cancer 松浦綾子 Journal of Japanese Society of Pharmaceutical Oncology 25: 202-202, 2022.

	S4-3. From the Qol cancer support drugstore to the specialized medical institution cooperation drugstore (cancer) 笹原侑祐 Journal of Japanese Society of Pharmaceutical Oncology 25: 203-203, 2022.

	S4-4. Follow-up and feedback ... led by patients with form - cancer of the cooperation to begin with the continuous pharmaceutical management 久田健登 Journal of Japanese Society of Pharmaceutical Oncology 25: 204-204, 2022.

	S7-1. About the cancer education in the school 咲間悟 Journal of Japanese Society of Pharmaceutical Oncology 25: 205-205, 2022.

	S7-2. Having learned from cancer education, learning from now on 丑木紅音 Journal of Japanese Society of Pharmaceutical Oncology 25: 206-206, 2022.

	S7-3. With a pharmacist sought by cancer education? 川田亮 Journal of Japanese Society of Pharmaceutical Oncology 25: 207-207, 2022.

	S7-4. What we want to know from the position of the patients with cancer outside lecturer 岸田徹 Journal of Japanese Society of Pharmaceutical Oncology 25: 208-208, 2022.

	S7-5. It is cancer education ... getting to the bottom of ... learning to you who live in from this now 儀賀理暁, 山口雅利, 杉山亜斗, 青木耕平, 羽藤泰, 福田祐樹, 河野光智, 中山光男 Journal of Japanese Society of Pharmaceutical Oncology 25: 209-209, 2022.

	S10-1. Treatment ... which snuggled up to cancer treatment and nourishment ... patients 滝澤康志 Journal of Japanese Society of Pharmaceutical Oncology 25: 210-210, 2022.

	S10-2. Cooperation with nourishment intervention and the pharmacist of the dietitian to chemotherapy patients 千歳はるか Journal of Japanese Society of Pharmaceutical Oncology 25: 211-211, 2022.

	S10-3. Nourishment support ... in nourishment management - formulations juxtaposition type drugstore to the cancer-treated patients which community pharmacy pharmacist carries 藤田あゆみ Journal of Japanese Society of Pharmaceutical Oncology 25: 212-212, 2022.

	S11-1. With the academic D tailing affecting the prescription behavior 小茂田昌代 Journal of Japanese Society of Pharmaceutical Oncology 25: 213-213, 2022.

	S11-2. The academic D tailing which established a viewpoint to be different of the pharmacologic action 斎藤顕宜 Journal of Japanese Society of Pharmaceutical Oncology 25: 214-214, 2022.

	S11-3. We think about biological molecule and pharmaceutical products about pain from structure 伊藤俊将 Journal of Japanese Society of Pharmaceutical Oncology 25: 215-215, 2022.

	S11-4. Practice of PBPM based on the constipation therapeutic drug academic D tailing to patients with cancer and the effect 木村敦, 都築竜太, 青柳友彦, 河本怜史, 香取哲哉, 淺野亜佑美, 伊勢美樹子, 岡元るみ子, 出雲貴文, 小茂田昌代 Journal of Japanese Society of Pharmaceutical Oncology 25: 216-216, 2022.

	S11-5. Crisis of Japanese traditional prescription custom 関根郁夫 Journal of Japanese Society of Pharmaceutical Oncology 25: 217-217, 2022.

	It is ... from Ayumi of clinical tumor Pharmaceutical Society and thing - growth to expect in future JASPO in the future to maturity 加藤裕芳 Journal of Japanese Society of Pharmaceutical Oncology 25: 218-218, 2022.

	It is ... from Ayumi of clinical tumor Pharmaceutical Society and thing - growth to expect in future JASPO in the future to maturity 遠藤一司 Journal of Japanese Society of Pharmaceutical Oncology 25: 219-219, 2022.

	S1-1. The cancer practice hospital cooperation training: The current situation and problem 縄田修一 Journal of Japanese Society of Pharmaceutical Oncology 25: 220-220, 2022.

	S1-2. Report from the training history examination subcommittee 樋口昇大 Journal of Japanese Society of Pharmaceutical Oncology 25: 221-221, 2022.

	S1-3. The way of the specialized medical institution cooperation drugstore system and pharmacy education 濃沼政美 Journal of Japanese Society of Pharmaceutical Oncology 25: 222-222, 2022.

	S1-4. Role to expect of the specialized medical institution cooperation drugstore (cancer) 川上貴裕 Journal of Japanese Society of Pharmaceutical Oncology 25: 223-223, 2022.

	S1-5. Accept the cancer practice hospital cooperation training; and from the situation of ... training hospital - 内山将伸, 吹上勇真, 萩原知佳, 福江悠香, 松尾宏一 Journal of Japanese Society of Pharmaceutical Oncology 25: 224-224, 2022.

	S1-6. Participate in the cancer practice hospital cooperation training; and from the position of the person of ... training 1 - 八坂瑞臣 Journal of Japanese Society of Pharmaceutical Oncology 25: 225-225, 2022.

	S1-7. Participate in the cancer practice hospital cooperation training; and from the position of the person of ... training 2 - 小林優樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 226-226, 2022.

	S3-1. Infection practice support of patients with cancer judging from pharmacokinetics 浜田幸宏 Journal of Japanese Society of Pharmaceutical Oncology 25: 227-227, 2022.

	S3-2. Antimicrobial management in the cancer cachexia patients 中山裕一 Journal of Japanese Society of Pharmaceutical Oncology 25: 228-228, 2022.

	S3-3. Antimicrobial management of the foreign chemotherapy 宮本康敬, 平野公美, 八木貴彦, 田中千穂, 外山未来 Journal of Japanese Society of Pharmaceutical Oncology 25: 229-229, 2022.

	S3-4. The antimicrobial management of the blood tumor domain 小井土啓一 Journal of Japanese Society of Pharmaceutical Oncology 25: 230-230, 2022.

	S5-1. Efforts for the inflection of PRO-CTCAE 川口崇 Journal of Japanese Society of Pharmaceutical Oncology 25: 231-231, 2022.

	S5-2. The case that reported diarrhea during Pembrolizumab therapy for cancer of endometrium with MSI-High 東加奈子 Journal of Japanese Society of Pharmaceutical Oncology 25: 232-232, 2022.

	S5-3. The case that reported digestive organ symptoms such as retching, vomiting, and the like during the Lenvatinib remedy for the hepatocellular carcinoma 平手大輔 Journal of Japanese Society of Pharmaceutical Oncology 25: 233-233, 2022.

	S5-4. Thought necessary for the pathologic reasoning 北原加奈之 Journal of Japanese Society of Pharmaceutical Oncology 25: 234-234, 2022.

	S8-1. Randomized, double-blind noninferiority trial of 1 mg for 3 mg of granisetron which we performed in Shizuoka 辻大樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 235-235, 2022.

	S8-2. Phase III study (TRIPLE study) that tested an advantage of palonosetron for granisetron in HEC 鈴木賢一 Journal of Japanese Society of Pharmaceutical Oncology 25: 236-236, 2022.

	S8-3. Phase III study (J-FORCE study) that tested an extra effect of olanzapine for three-drug standard antiemesis therapy of HEC 橋本浩伸 Journal of Japanese Society of Pharmaceutical Oncology 25: 237-237, 2022.

	S8-4. Noninferiority trial (SPARED trial) that tested Steroid sparing in HEC 湊川紘子, 伊藤由香 Journal of Japanese Society of Pharmaceutical Oncology 25: 238-238, 2022.

	S8-5. Expectation to a pharmacist sending evidence 山本信之 Journal of Japanese Society of Pharmaceutical Oncology 25: 239-239, 2022.

	S12-1. Clinical studies to push forward by the team led by foreign chemotherapy patients 二瓶哲 Journal of Japanese Society of Pharmaceutical Oncology 25: 240-240, 2022.

S12-2. Search of the prophylaxis for the anticancer agent-induced side effect of study technique that fused with medical big data analysis in fundamental researches
合田光寛, 神田将哉, 吉岡俊彦, 新村貴博, 櫻田巧, 小川敦, 岡田直人, 相澤風花, 八木健太, 濱野裕章, 石澤有紀, 座間味義人, 石澤啓介
Journal of Japanese Society of Pharmaceutical Oncology 25: 241-241, 2022.

	S12-3. It is ... from the each point of clinical studies - adverse event management to work on in the viewpoint of the clinical pharmacist 齋藤佳敬 Journal of Japanese Society of Pharmaceutical Oncology 25: 242-242, 2022.

	S12-4. It is ... mainly on the evaluation of practice - supportive care, the side effect of clinical studies in consideration of Feasibility in the cancer domain 野田哲史 Journal of Japanese Society of Pharmaceutical Oncology 25: 243-243, 2022.

	O-1. Comparison of the frequencies of a malignant tumor with the methotrexate therapy for the rheumatoid arthritis using the large-scale insurance claim information and the malignant tumor in Japan 中村有沙, 豕瀬諒, 大見里奈, 岳野秀二郎, 村木優一 Journal of Japanese Society of Pharmaceutical Oncology 25: 244-244, 2022.

	O-2. The calculation situation of a cancer treatment support system and specific drug management instruction addition 2 of our drugstore toward the highly pharmaceutical management function drugstore 太田和綾, 高橋絵梨子, 須賀公美, 丹波智子, 長尾昌哉, 関和博, 生田聡子 Journal of Japanese Society of Pharmaceutical Oncology 25: 245-245, 2022.

	O-3. Usefulness evaluation of the checking prescription system in consideration of the effect degree of drug interactions 尾花美由樹, 滝澤健司, 小賀春菜, 山本歩実 Journal of Japanese Society of Pharmaceutical Oncology 25: 246-246, 2022.

O-4. Effect of the combination of the histamine H2 receptor blocker on effectiveness of the capecitabine therapy in patients with colon cancer: Look at the multicenter rear; a mark observational study
細川祐岐, 北爪賀子, 河添仁, 魚住龍史, 吉澤朝枝, 飯原大稔, 藤井宏典, 高橋正也, 新井隆広, 佐藤由美子, 三上貴弘, 横山敦, 山崎朋子, 高橋克之, 藤田行代志, 村地康, 諸角一成, 土屋雅美, 橋本浩伸, 山口正和
Journal of Japanese Society of Pharmaceutical Oncology 25: 247-247, 2022.

	O-5. Analysis about the cardiac activity disorder by VEGFR-TKI 高田慎也, 梅原健吾, 橋野泰良, 佐藤秀紀, 山岸佳代, 丸山覚, 原林透, 美濃興三 Journal of Japanese Society of Pharmaceutical Oncology 25: 248-248, 2022.

	O-6. Optimum doses of olanzapine in the antiemesis therapy of the cancer chemotherapy 神崎愛, 真島宏太, 井上竜一, 川田哲史, 江越菜月, 池内忠宏, 兼重晋, 緒方憲太郎, 神村英利 Journal of Japanese Society of Pharmaceutical Oncology 25: 249-249, 2022.

	O-7. Pilot investigation about the utility of the Lenvatinib side effect expression predictive supporting tool in the hepatocellular carcinoma 原伸輔, 新谷拓也, 山本智也, 奥田真弘 Journal of Japanese Society of Pharmaceutical Oncology 25: 250-250, 2022.

	O-8. Fact-finding of the delayed immune-mediated adverse event in patients with non-small cell lung cancer which produced an immune-mediated adverse event within one year after a checkpoint inhibitor start of immunity 馬場楓, 佐野慶行, 葉清隆, 川崎敏克 Journal of Japanese Society of Pharmaceutical Oncology 25: 251-251, 2022.

	O-9. Clinical features of 21 patients with type I diabetes mellitus that occurred by an immune checkpoint inhibitor 廣正拓也, 田内淳子, 小柴郁, 魚井みゆき, 久松大祐, 宮田篤, 亀岡春菜, 高田慎也, 松井礼子, 大橋健, 川崎敏克 Journal of Japanese Society of Pharmaceutical Oncology 25: 252-252, 2022.

	O-10. We examine cancer disease and evaluate the usefulness of the medicine cooperation workshop 国吉央城, 中里健志, 塚田昌樹, 沖田彩, 新井亘 Journal of Japanese Society of Pharmaceutical Oncology 25: 253-253, 2022.

O-11. Efforts of the Fukuoka University hospital pharmacy for the HBV reactivation prevention in the oral anticancer medicine remedy patients
福山景子, 柿本秀樹, 長郷あかね, 大倉野将広, 江口幸臣, 真島宏太, 角康隆, 武田佳子, 江越菜月, 池内忠宏, 兼重晋, 緒方憲太郎, 神村英利
Journal of Japanese Society of Pharmaceutical Oncology 25: 254-254, 2022.

	O-12. Study on quantity of scattering reduction effect of the appropriate procedure in injectable anticancer agent preparation duties 柳澤友希, 伊佐間和郎, 黒須智博, 夏目義明, 清野敏一, 西村哲治, 山下敦志 Journal of Japanese Society of Pharmaceutical Oncology 25: 255-255, 2022.

	O-13. Inspection of the paclitaxel decontamination effect of the ozonization alcohol spray 森本麻友, 平畠正樹, 入江慶, 橋田亨, 吉田英一, 室井延之 Journal of Japanese Society of Pharmaceutical Oncology 25: 256-256, 2022.

	O-14. Evaluation of the contribution of pharmacists to medical safety in outpatient cancer treatment - Analysis of reported pre-avoid cases - 村瀬寛美, 郷真貴子, 山田志緒里, 西村充礼, 松山卓矢, 吉村知哲 Journal of Japanese Society of Pharmaceutical Oncology 25: 257-257, 2022.

	O-15. Washing effect of the shirt contaminated with the sweat of a large quantity of Cyclophosphamide treated patients 谷川大夢, 丸谷善紀, 鈴木優司, 廣原正宜, 串田一樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 258-258, 2022.

	O-16. Examination about the quantity of cyclophosphamide detected in the sweat of patients after the CHOP therapy 宮澤真帆, 山下理菜, 井口麻美, 羽田真理子, 針ヶ谷義久, 一戸唯, 香西康司, 廣井順子, 岸本桂子, 寺山義泰 Journal of Japanese Society of Pharmaceutical Oncology 25: 259-259, 2022.

	From a viewpoint of expectation - cancer medical therapy to clinical oncological development and pharmacist - 石岡千加史 Journal of Japanese Society of Pharmaceutical Oncology 25: 260-260, 2022.

	S6-1. Tips about a system summary and the procedure for APACC/BPACC 小井土啓一 Journal of Japanese Society of Pharmaceutical Oncology 25: 261-261, 2022.

	S6-2. Example examination: We will think by a viewpoint "doing" 下川友香理 Journal of Japanese Society of Pharmaceutical Oncology 25: 262-262, 2022.

	S6-3. An interview examination: We will think by a viewpoint "doing" 小澤有輝 Journal of Japanese Society of Pharmaceutical Oncology 25: 263-263, 2022.

	S9-1. Limit - of problem - prescribed medicine in side effect measures of the anticancer medicine 郷真貴子 Journal of Japanese Society of Pharmaceutical Oncology 25: 264-264, 2022.

	S9-2. Embarrassing event ... about the commercial drug which actually met during patients support - outpatient department cancer medical therapy by the hospital pharmacist 藤堂真紀 Journal of Japanese Society of Pharmaceutical Oncology 25: 265-265, 2022.

	S9-3. Is only patients support - prescribed medicine by the collaboration of a hospital, a drugstore, the drugstore enough for the side effect measures? 服部和俊 Journal of Japanese Society of Pharmaceutical Oncology 25: 266-266, 2022.

	S9-4. Patients support by the drugstore pharmacist 友部賢 Journal of Japanese Society of Pharmaceutical Oncology 25: 267-267, 2022.

	S9-5. Pharmacist cooperation in the community medical care 小原道子 Journal of Japanese Society of Pharmaceutical Oncology 25: 268-268, 2022.

	S13-1. At first, to take a starting line of the myeloma practice intellect no hearing ... in a treatment strategy of the multiple myeloma; ... 渡部大介 Journal of Japanese Society of Pharmaceutical Oncology 25: 269-269, 2022.

	S13-2. Autogenous graft is not scary; of the autologous peripheral blood stem cell transplantation combination salvage chemotherapy and supportive care, actually! 加藤淳平 Journal of Japanese Society of Pharmaceutical Oncology 25: 270-270, 2022.

	S13-3. A pharmacist become a central figure; is side effect measures in the multiple myeloma treatment 杉富行 Journal of Japanese Society of Pharmaceutical Oncology 25: 271-271, 2022.

	S13-4. How should we support? For How I treat which ... physician has, it is necessary for the pharmacist to have what kind of viewpoint; or ... 小室雅人 Journal of Japanese Society of Pharmaceutical Oncology 25: 272-272, 2022.

	S14-1. Importance of the long-term follow-up by the healthcare worker thinking through cancer experience 佐野元彦 Journal of Japanese Society of Pharmaceutical Oncology 25: 273-273, 2022.

	S14-2. Importance of the late complications of children, AYA generation cancer and the long-term follow-up 前田美穗 Journal of Japanese Society of Pharmaceutical Oncology 25: 274-274, 2022.

	S14-3. Viewpoint ... of problem and importance - pharmacy student survivor of the long-term follow-up whom a childhood cancer experienced person faces 加藤美和 Journal of Japanese Society of Pharmaceutical Oncology 25: 275-275, 2022.

	S14-4. It is ... from the viewpoint of need - pharmacist survivor of the seamless long-term follow-up depending on a life event 小松敏彰 Journal of Japanese Society of Pharmaceutical Oncology 25: 276-276, 2022.

	S17-1. Tell, and help you, and a pharmacist! 桜井なおみ Journal of Japanese Society of Pharmaceutical Oncology 25: 277-277, 2022.

	S17-2. One point of an adverse event and the working support in the cancer chemotherapy 縄田修一 Journal of Japanese Society of Pharmaceutical Oncology 25: 278-278, 2022.

	S17-3. Working support of patients with cancer which even a pharmacist has, one step of the beginning 土屋雅美 Journal of Japanese Society of Pharmaceutical Oncology 25: 279-279, 2022.

	S17-4. Dispatch ... from role - Kanagawa of the pharmacist in the working support of patients with cancer 橋口宏司 Journal of Japanese Society of Pharmaceutical Oncology 25: 280-280, 2022.

	S17-5. Dispatch ... from working support - Okinawa that a pharmacist receives 山本紗織 Journal of Japanese Society of Pharmaceutical Oncology 25: 281-281, 2022.

	S17-6. Example of the coexistence support in CALBEE 武田雅子 Journal of Japanese Society of Pharmaceutical Oncology 25: 282-282, 2022.

	S17-7. Example of the employment support in the medium and small-sized business 櫻井公恵 Journal of Japanese Society of Pharmaceutical Oncology 25: 283-283, 2022.

	S20-2. What are evaluation method - proportion hazard characteristics, RMST of data for survival time? - 林行和 Journal of Japanese Society of Pharmaceutical Oncology 25: 285-285, 2022.

	S20-3. Polite, plain "COA" (Clinical Outcome Assessment) 山口拓洋 Journal of Japanese Society of Pharmaceutical Oncology 25: 286-286, 2022.

	S20-4. estimand - What you want to know and what you can know - 菅波秀規 Journal of Japanese Society of Pharmaceutical Oncology 25: 287-287, 2022.

	S21-1. Current situation and problem ... of community medical care cooperation in the extensive acute phase hospital and role - pharmacist cooperation of the pharmacist 三沖大介 Journal of Japanese Society of Pharmaceutical Oncology 25: 288-288, 2022.

	S21-2. About the current situation and a problem of the pharmacist cooperation in the local core hospital 島田健, 大里勇二, 江本文代, 中村祥敬, 畑中由香子 Journal of Japanese Society of Pharmaceutical Oncology 25: 289-289, 2022.

	S21-3. ... which confronts the calculation situation of the cooperation full addition in the district hospital and problems of invention - pharmacist cooperation 中永かおり Journal of Japanese Society of Pharmaceutical Oncology 25: 290-290, 2022.

	S21-4. The current situation and problem of the pharmacist cooperation to be connected from calculation of specific drug management instruction addition 2 in the health insurance pharmacy 泉憲政 Journal of Japanese Society of Pharmaceutical Oncology 25: 291-291, 2022.

	S21-5. All Hyogo, setting ... of foreign chemotherapy support ... advanced drug duties special committee to work in all pharmacists (Hyogo hospital pharmacist society, pharmacist society) 辻井聡容 Journal of Japanese Society of Pharmaceutical Oncology 25: 292-292, 2022.

	S23-1. Problems faced by AYA cancer patients - the social situation surrounding them and what medical professionals can do - 尾上琢磨 Journal of Japanese Society of Pharmaceutical Oncology 25: 293-293, 2022.

	S23-2. Information to support the life of the patients with juvenile cancer which we want to know as a pharmacist 日置三紀 Journal of Japanese Society of Pharmaceutical Oncology 25: 294-294, 2022.

	S23-3. Cooperation ... with a pharmacist and other types of job to see from team approach ... case to patients with juvenile cancer 宇田川涼子 Journal of Japanese Society of Pharmaceutical Oncology 25: 295-295, 2022.

O-29. Preparation of anticancer drug follow-up sheets by pharmacists and hospital pharmacists - Saitama Regional Cooperation Network, Cancer WG -
新津京介, 新井一也, 大木崇弘, 川口諭, 川口こずえ, 桐生寛一, 後藤孝之, 田口徹, 中園卓臣, 原朋美, 樋下田香織, 山中美和, 吉田憲司, 渡邊健太, 鈴木栄, 長谷部忠史, 野田政充
Journal of Japanese Society of Pharmaceutical Oncology 25: 296-296, 2022.

	O-30. Role - of the pharmacist in current situation and problem - gene clinical department of the examination for oncogene panel in the Aizawa Hospital 野村充俊, 木村純子, 茂木英明 Journal of Japanese Society of Pharmaceutical Oncology 25: 297-297, 2022.

	O-31. The current situation investigation and usefulness evaluation of the efforts about the cooperation full addition in our hospital 中西一志, 塩川尚恵, 三井満里奈, 安島秀友, 松崎貴志, 田中恒明 Journal of Japanese Society of Pharmaceutical Oncology 25: 298-298, 2022.

	O-32. The effect that medicine medicine cooperation through the foreign cooperation full addition gives for foreign chemotherapy 小中健, 斉藤辰彦, 伊藤祥子, 森本美由樹, 黒田武志, 都築大輔, 伏谷秀治 Journal of Japanese Society of Pharmaceutical Oncology 25: 299-299, 2022.

	O-33. Examination of the usefulness of the information provided from the health insurance pharmacy accompanied with the cooperation full addition calculation start 井上将貴, 川澄賢司, 松井礼子, 佐藤信恵, 岩本義弘, 田中将貴, 馬見新佳那子, 金子明日美, 川崎敏克 Journal of Japanese Society of Pharmaceutical Oncology 25: 300-300, 2022.

	O-34. The good use of medicine medicine cooperation tool situation investigation of the health insurance pharmacy pharmacist in the foreign cancer chemotherapy 木村江理香, 高崎新也, 堀川美帆, 松浦正樹, 前川正充, 眞野成康 Journal of Japanese Society of Pharmaceutical Oncology 25: 301-301, 2022.

O-35. Prescription intervention by the medicine medicine cooperation using the tracing report in the foreign cancer medical therapy and evaluation of the usefulness
槙原克也, 基村佳世, 福井梨乃, 奥澤文敏, 井上聖夜子, 松村友和, 吉留実慧子, 喜田博美, 財前美夏子, 平尾昴士, 吉岡幸洋, 伊戸郷美
Journal of Japanese Society of Pharmaceutical Oncology 25: 302-302, 2022.

	O-36. About the cancer practice hospital cooperation training, it is the results and a problem, consideration in our center 中澤紘, 平尾勇太, 新津京介, 鈴木栄, 長谷部忠史 Journal of Japanese Society of Pharmaceutical Oncology 25: 303-303, 2022.

	O-37. Fact-finding of dietitian - pharmacist cooperation situation about foreign cancer-treated patients 齋藤里乃, 川崎祐介, 下村直樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 304-304, 2022.

	O-44. Drug history management and drug coordination in azacitidine plus venetoclax therapy for acute myeloid leukemia (AML) 齊藤菜奈, 春田貴史, 内藤梨奈, 田嶋梓, 遠藤恵理, 江藤壮志, 林恵子, 林みどり, 安田江里子 Journal of Japanese Society of Pharmaceutical Oncology 25: 305-305, 2022.

	O-45. Analysis ... with the tracing report of prescription suggestion contents and the adoption rate - Aichi cancer center of the drugstore pharmacist in the cancer medical therapy 則武千波夜, 前田章光, 高野裕佑, 須田貴斗, 増田明莉, 伊藤裕子, 松崎雅英 Journal of Japanese Society of Pharmaceutical Oncology 25: 306-306, 2022.

	O-46. PBPM effect in the HEC-CCR adaptation patients 鈴木寛人, 築田晃直, 平田亮介, 仲本敦, 河崎英範, 津曲恭一, 山形真一 Journal of Japanese Society of Pharmaceutical Oncology 25: 307-307, 2022.

	O-47. Case report of the medicine medicine cooperation that clinical record reading and tracing report combination utilizing the ICT were useful in the foreign chemotherapy 井上靖隆, 寺谷俊昭, 山本明日香, 高口弘美, 上田晃, 川本由加里, 中村路夫, 後藤仁和 Journal of Japanese Society of Pharmaceutical Oncology 25: 308-308, 2022.

	O-48. Efforts by the palliative care team of our hospital for the self-care promotion of the opioid rescue medicine 久松大祐, 泊由布子, 田ノ上美依菜, 今村繭子, 樋口文子, 岡本正博, 門田芳幸, 後藤隆, 清水裕彰 Journal of Japanese Society of Pharmaceutical Oncology 25: 309-309, 2022.

	O-49. About efforts to polypharmacy in the national cancer research center center Hospital 東郁子, 渡部大介, 石川光信, 赤木徹, 橋本浩伸, 古川哲也 Journal of Japanese Society of Pharmaceutical Oncology 25: 310-310, 2022.

	O-50. Efforts of the supportive care prescription representation input in the foreign cancer chemotherapy 畠山智明, 遠藤美央, 鈴木拓也, 玉木慎也 Journal of Japanese Society of Pharmaceutical Oncology 25: 311-311, 2022.

	O-51. The current situation, attitude survey about the cancer chemotherapy for health insurance pharmacies of Ehime 大野貴之, 亀岡春菜, 矢野琢也, 竹内信人, 田中守, 松久哲章, 浅川隆重, 古川清, 青儀健二郎, 小池恭正 Journal of Japanese Society of Pharmaceutical Oncology 25: 312-312, 2022.

	O-52. Usefulness and regional alliances of the tracing report introduction for local unification 徳留章, 佐藤彩伽, 齋藤靖弘, 八木澤啓司, 鈴木直哉, 辻裕太, 藤村拓也, 重成大介, 菊池健, 谷口亮央, 樋浦一哉, 山下美妃, 木明貴幸 Journal of Japanese Society of Pharmaceutical Oncology 25: 313-313, 2022.

	The distance of the restoration revival of the care medical from a damage of Rikuzentakata-shi and future problem 石木幹人 Journal of Japanese Society of Pharmaceutical Oncology 25: 314-314, 2022.

	S15-1. Workshop of the online era, facilitation outline 下村昭彦 Journal of Japanese Society of Pharmaceutical Oncology 25: 315-315, 2022.

	S15-2. Instantaneous power of the facilitation does not work? The online workshop which you do for what 大里洋一 Journal of Japanese Society of Pharmaceutical Oncology 25: 316-316, 2022.

	S15-3. Online journal club activities to link Japan and the world 土屋雅美 Journal of Japanese Society of Pharmaceutical Oncology 25: 317-317, 2022.

	S15-4. Form of the next-generation academic conference where XR of the academic meeting looks like from becoming it 枷場博文 Journal of Japanese Society of Pharmaceutical Oncology 25: 318-318, 2022.

	S18-1. Intervention from a pharmacist viewpoint by the team Lenvatinib for patients with hepatocytes cancer 森下滉己 Journal of Japanese Society of Pharmaceutical Oncology 25: 319-319, 2022.

	S18-2. Response to Lenvatinib adverse event by the medicine medicine cooperation 新谷裕子 Journal of Japanese Society of Pharmaceutical Oncology 25: 320-320, 2022.

	S18-3. How to use risk communication tools in hepatocellular carcinoma treatment 篠原旭 Journal of Japanese Society of Pharmaceutical Oncology 25: 321-321, 2022.

	S18-4. We expect it of new treatment strategy - pharmacist for the hepatocellular carcinoma 小暮高之, 佐藤麻理, 佐藤賢一 Journal of Japanese Society of Pharmaceutical Oncology 25: 322-322, 2022.

	O-17. Renal function evaluation based on cystatin C in patients with urothelial carcinoma which a therapy with gemcitabine and cisplatin was given in 西村文宏, 池上孝明, 堀尾美世, 牛島智子, 濱田真輔, 門脇大輔, 宮村重幸, 鬼木健太郎, 猿渡淳二 Journal of Japanese Society of Pharmaceutical Oncology 25: 323-323, 2022.

	O-18. Examination of the effect to the relative intensity of treatment of XELOX-treated patients by the pharmacist outpatient department intervention 桝茂典, 影山明, 中村悠美, 中川隼一, 茂原圭佑, 塚崎雄平, 平島徹 Journal of Japanese Society of Pharmaceutical Oncology 25: 324-324, 2022.

	O-19. Analysis of the association between expression and menopause and hyperemesis of chemotherapy-induced retching, vomiting 米澤樹, 辻大樹, 小玉千佳, 松本恵実, 山本圭祐, 鈴木賢一, 宮城壮裕, 中道秀徳, 矢部勝茂, 伊藤邦彦 Journal of Japanese Society of Pharmaceutical Oncology 25: 325-325, 2022.

	O-20. Examination of the risk factor about onset of febrile neutropenia in the 5-FU+CDDP+ radiotherapy for the cancer of the esophagus 衛藤大輝, 白岩健, 田中遼大, 龍田涼佑, 伊東弘樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 326-326, 2022.

	O-21. Effect by the early intervention of the lacrimal expression and pharmacist in the S-1-containing regimen 村田菜乃美, 野口善久, 土居真純, 床西冴月, 川尻成美 Journal of Japanese Society of Pharmaceutical Oncology 25: 327-327, 2022.

	O-22. Examination of the risk factor of the infusion reaction expression by the trastuzumab 堀真悠子, 島貫裕実子, 下村昭彦, 小室雅人, 谷山智子, 寺門浩之, 清水千佳子 Journal of Japanese Society of Pharmaceutical Oncology 25: 328-328, 2022.

	O-23. Comparison of delirium frequencies in the induction of a morphine internal use agent and the hydromorphone internal use agent 田中大智, 田中怜, 森本重輝, 鴨志田武, 石川寛, 佐藤哲, 佐藤哲観, 斎藤顕宜, 山田大輔, 近藤美奈, 高橋健二, 高橋千惠子, 篠道弘 Journal of Japanese Society of Pharmaceutical Oncology 25: 329-329, 2022.

	O-24. Examination about the onset of peripheral edema in the gemcitabine + paclitaxel (albumin suspension type) therapy 松山卓矢, 浅野裕紀, 守屋昭宏, 竹中翔也, 伊藤大輔, 岩井美奈, 吉村知哲 Journal of Japanese Society of Pharmaceutical Oncology 25: 330-330, 2022.

	O-25. Usefulness of the pre-medication for the infusion reaction prevention in patients receiving trastuzumab single agent 島田浩和, 大神正宏, 鈴木嘉治, 立原茂樹, 坪山勝平, 小島友恵, 柴このみ, 鈴木美加 Journal of Japanese Society of Pharmaceutical Oncology 25: 331-331, 2022.

	O-26. Fact-finding of the combination treatment (nivolumab + Ipilimumab) in our hospital of immunity 濱武清範, 小西史子, 野間敏也, 橋本仁美, 福井美礼, 仲忠士, 美和孝之, 小島一晃, 北英夫 Journal of Japanese Society of Pharmaceutical Oncology 25: 332-332, 2022.

	O-27. Evaluation of the antiemesis therapy in patients with multiple myeloma that received an autologous peripheral blood stem cell transplantation combination melphalan massive dose therapy 加藤淳平, 渡邊健人, 松本千明, 立田真也, 石田耕太, 細谷治, 塚田信弘, 石田禎夫 Journal of Japanese Society of Pharmaceutical Oncology 25: 333-333, 2022.

	O-28. Usefulness of the medical therapy for peripheral neuropathy by the albumin suspension type paclitaxel 高橋果子, 野口善久, 土居真純, 床西冴月, 村田菜乃美, 川尻成美 Journal of Japanese Society of Pharmaceutical Oncology 25: 334-334, 2022.

	O-38. Examination of the bendamustine-related angiopathic expression factor in patients with non-Hodgkin's lymphoma 梅原健吾, 高田慎也, 佐藤秀紀, 山岸佳代, 藤本勝也, 黒澤光俊, 美濃興三 Journal of Japanese Society of Pharmaceutical Oncology 25: 335-335, 2022.

	O-39. Content analysis of the follow-up during the remedy period of the pharmacist to the specific drug management instruction addition 2 calculation patients 足立昇平, 下川友香理, 本田雅志, 坂口敦彦, 原田素子, 正木研, 本村真悟, 牧りえ, 荒井元志, 中村泰朗 Journal of Japanese Society of Pharmaceutical Oncology 25: 336-336, 2022.

	O-40. Attitude survey of patients for the side effect measures prescription of the breast cancer outpatient department chemotherapy 池田樹生 Journal of Japanese Society of Pharmaceutical Oncology 25: 337-337, 2022.

	O-41. Investigation about the relative dose intensity of the dose-dense AC therapy in patients with old breast cancer 鶴島克将, 柳下祐貴子, 小川直希, 藤井千賀, 安井友佳子, 武田朋也, 椿正寛, 西田升三, 石坂敏彦, 山村順, 神垣俊二 Journal of Japanese Society of Pharmaceutical Oncology 25: 338-338, 2022.

	O-42. Survey on the use of immune checkpoint inhibitors in respiratory surgery at Keiyukai Sapporo Hospital 岩本浩史, 早坂洲生, 竹内公実 Journal of Japanese Society of Pharmaceutical Oncology 25: 339-339, 2022.

	O-43. Example introduction of the current situation of the follow during the remedy period by the drugstore pharmacist for patients with cancer and the follow that we continued 松下隼士, 伊藤駿, 川浪望恵, 金松里奈, 三笘祥子, 新地聖子, 三浦誠, 小川愛, 廣瀬隆 Journal of Japanese Society of Pharmaceutical Oncology 25: 340-340, 2022.

	O-53. Costs estimation of the systemic chemotherapy in the unresectable pancreatic cancer using real world data 浅見新, 柴原遼太郎, 宅本悠希, 赤沢学 Journal of Japanese Society of Pharmaceutical Oncology 25: 341-341, 2022.

	O-54. Can you test the results obtained from the adverse event spontaneous report database in large-scale insurance claim information? 大見里奈, 豕瀬諒, 中村有沙, 岳野秀二郎, 村木優一 Journal of Japanese Society of Pharmaceutical Oncology 25: 342-342, 2022.

	O-55. Treatment fact-finding of the systemic chemotherapy for the Japanese unresectable pancreatic cancer 柴原遼太郎, 浅見新, 宅本悠希, 赤沢学 Journal of Japanese Society of Pharmaceutical Oncology 25: 343-343, 2022.

	O-56. The antitumor effect with the therapy with antiPD-1/PD-L1 antibody and other anticancer agents in the solid carcinoma: A systematic review and meta-analysis 井上崇, 成川衛 Journal of Japanese Society of Pharmaceutical Oncology 25: 344-344, 2022.

	O-57. One case of local recurrence carcinoma of the buccal mucosa that algetic sedative management associated with treatment in the yl Minox therapy and affected part necrosis was accomplished 佐藤春菜, 杉崎一輝, 鎌田隼, 渋谷悠真, 川之辺淳, 鈴木真也, 篠崎剛, 林隆一, 川崎敏克 Journal of Japanese Society of Pharmaceutical Oncology 25: 345-345, 2022.

	O-58. One patient who detected severe erythema-like dermatopathy by Weekly paclitaxel + Carboplatin + radiation combination therapy 高橋佳孝, 板倉祥嗣, 苅田明子, 小森桂子, 舩越真理, 笹田碧沙, 塩津伸介, 土谷有美 Journal of Japanese Society of Pharmaceutical Oncology 25: 346-346, 2022.

	O-59. The best case of patients with hepatocellular carcinoma with the autoimmune disease that developed severe irAE myositis after the Atezolizumab + bevacizumab therapy enforcement 末繁嘉朗, 白岩健, 田中遼大, 龍田涼佑, 伊東弘樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 347-347, 2022.

	O-60. The case that affected PCA pump introduction and that of cancer terminal 和田憲周, 林智子, 山本侑記, 藤井美和子 Journal of Japanese Society of Pharmaceutical Oncology 25: 348-348, 2022.

	O-61. One case of patients with recurrent colon cancer which we called and were following up cholinergic syndrome of irinotecan and suspected 粟野友美 Journal of Japanese Society of Pharmaceutical Oncology 25: 349-349, 2022.

	S22-1. We think about pharmaceutical cooperation for a hint in internal secretion irAE 槙田紀子 Journal of Japanese Society of Pharmaceutical Oncology 25: 350-350, 2022.

	S22-2. How do bring up collective strength to support irAE; from the position of the ... University teacher - 林稔展 Journal of Japanese Society of Pharmaceutical Oncology 25: 351-351, 2022.

	S22-3. Problems ... in ... community pharmacy thinking that a health insurance pharmacy pharmacist can do it 長久保久仁子 Journal of Japanese Society of Pharmaceutical Oncology 25: 352-352, 2022.

	S22-4. The point ... "analysis power" and "sixth sense?" 吉野真樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 353-353, 2022.

	S24-1. What we want to convey than the experience of Granisetron study, the PATROL-I study 中垣繁 Journal of Japanese Society of Pharmaceutical Oncology 25: 354-354, 2022.

	S24-2. "Experience and trouble of the contact as an allotment organization" to talk about from the experience of the SPARED study 稲田佑亮 Journal of Japanese Society of Pharmaceutical Oncology 25: 355-355, 2022.

	S24-3. We talk from the experience of the ASTRO study 国吉央城 Journal of Japanese Society of Pharmaceutical Oncology 25: 356-356, 2022.

	S24-4. From the viewpoint of the physician: How were you able to accomplish the EASED study? 森雅紀 Journal of Japanese Society of Pharmaceutical Oncology 25: 357-357, 2022.

	S24-5. Academia be made for the clinical studies of the pharmacist 鈴木賢一 Journal of Japanese Society of Pharmaceutical Oncology 25: 358-358, 2022.

	S25-1. The present of point to keep in mind - cancer domain when use and application does large-scale medical information in this country 高田敦史 Journal of Japanese Society of Pharmaceutical Oncology 25: 359-359, 2022.

	S25-2. Possibility of the cancer practice support using the AI 佐藤弘康 Journal of Japanese Society of Pharmaceutical Oncology 25: 360-360, 2022.

	S25-3. Medication counseling using the video in the childhood medical therapy 岩西雄大 Journal of Japanese Society of Pharmaceutical Oncology 25: 361-361, 2022.

	S25-4. For a pharmacist climbing over coming hospital DX 小枝伸行 Journal of Japanese Society of Pharmaceutical Oncology 25: 362-362, 2022.

	S16-1. The acquaintance of the clinical ethic is ethic education plan ... of need or ... pharmacist for the pharmacist that it is why 川村和美 Journal of Japanese Society of Pharmaceutical Oncology 25: 363-363, 2022.

	S16-2. The ethical dilemma that a pharmacist meets with 吉澤朝枝 Journal of Japanese Society of Pharmaceutical Oncology 25: 364-364, 2022.

	S16-3. Facts, and the like of the ethic consultation about the cancer medical care 稲葉一人 Journal of Japanese Society of Pharmaceutical Oncology 25: 365-365, 2022.

	S16-4. About the current situation of an activity of Rousaibyoin, Yokohama and the clinical ethic consultation of the United States 楠瀬まゆみ Journal of Japanese Society of Pharmaceutical Oncology 25: 366-366, 2022.

	S19-1. About an international exchange of JASPO 鈴木真也 Journal of Japanese Society of Pharmaceutical Oncology 25: 367-367, 2022.

	S19-2. International exchange that a young person expects in the future 堀之内藍 Journal of Japanese Society of Pharmaceutical Oncology 25: 368-368, 2022.

	S19-3. Our goal is to provide the best support for cancer patients. That's why we have to get better all the time. The ESOP Way Meire Klaus Journal of Japanese Society of Pharmaceutical Oncology 25: 369-369, 2022.

	O-62. One patient who was treated effectively with lorazepam for Colin symptom in the pancreatic cancer FOLFIRINOX therapy 新美政樹, 浅井暁, 西川貴広, 尾畑景子, 福元幸子, 谷口結基, 小杉菜々子, 太田達也, 田中章郎 Journal of Japanese Society of Pharmaceutical Oncology 25: 370-370, 2022.

	O-63. 1 case that intervened in heart failure management under the cancer chemotherapy 出口桃子, 沢田佳祐, 守上裕子, 韓秀玄, 河野修治 Journal of Japanese Society of Pharmaceutical Oncology 25: 371-371, 2022.

	O-64. One case that clobetasol propionate ester shampoo was effective for scalp dermatitis acneiform during panitumumab administration 安島亜矢子, 此松晶子, 宮内秀典, 和田由大, 野口周作, 笠原英城 Journal of Japanese Society of Pharmaceutical Oncology 25: 372-372, 2022.

	O-65. One case of the follicular lymphoma which presented acute kidney, liver damage due to the tumor lysis syndrome after the Obinutuzumab + bendamustine therapy enforcement 白岩健, 田中遼大, 龍田涼佑, 伊東弘樹 Journal of Japanese Society of Pharmaceutical Oncology 25: 373-373, 2022.